<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5760-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ISENTRESS 600MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RALTEGRAVIR POTASSIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2239.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD International GmbH (Singapore Branch)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD International GmbH (Singapore Branch)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AX08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>What Isentress is</strong></p><p style="margin-left:5.9pt; margin-right:3.2pt; text-align:justify">Isentress contains the active substance raltegravir. Isentress is an antiviral medicine that works against the Human Immunodeficiency Virus (HIV). This is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>How Isentress works</strong></p><p style="margin-left:5.9pt; margin-right:6.7pt">The virus produces an enzyme called HIV integrase. This helps the virus to multiply in the cells in your body. Isentress stops this enzyme from working. When used with other medicines, Isentress may reduce the amount of HIV in your blood (this is called your &quot;viral load&quot;) and increase your CD4-cell</p><p style="margin-left:5.9pt; margin-right:3.05pt">count (a type of white blood cells that plays an important role in maintaining a healthy immune system to help fight infection). Reducing the amount of HIV in the blood may improve the functioning of</p><p style="margin-left:5.9pt; margin-right:-1.0pt">your immune system. This means your body may fight infection better.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>When Isentress should be used</strong></p><p style="margin-left:5.9pt; margin-right:-1.0pt">Isentress 600 mg film-coated tablets is used to treat adults and paediatric patients weighing at least</p><p style="margin-left:5.9pt; margin-right:-1.0pt">40 kg who are infected by HIV. Your doctor has prescribed Isentress to help control your HIV</p><p style="margin-left:5.9pt; margin-right:-1.0pt">infection.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Isentress:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to raltegravir or to any of the other ingredients in this medicine (listed in section&nbsp;6).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Isentress.</p><p>Remember that Isentress is not a cure for HIV infection. This means that you may keep getting infections or other illnesses associated with HIV. You should keep seeing your doctor regularly while taking this medicine.</p><p>&nbsp;</p><p><u>Mental health problems</u></p><p>Tell your doctor if you have a history of depression or psychiatric illness. Depression, including suicidal thoughts and behaviours, has been reported in some patients taking this medicine, particularly in patients with a prior history of depression or psychiatric illness.</p><p>&nbsp;</p><p><u>Bone problems</u></p><p>Some patients taking combination anti-retroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination anti-retroviral therapy, corticosteroid use, alcohol consumption, severe reduction of the activity of the immune system, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms, please inform your doctor.</p><p>&nbsp;</p><p><u>Liver problems</u></p><p>Tell your doctor, pharmacist or nurse if you have had problems with your liver before, including hepatitis&nbsp;B or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take this medicine.</p><p>&nbsp;</p><p><u>Infections</u></p><p>Tell your doctor, pharmacist or nurse<strong> </strong>immediately if you notice any symptoms of infection, such as fever, and/or feeling unwell. In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body&rsquo;s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.</p><p>&nbsp;</p><p>In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.</p><p>&nbsp;</p><p><u>Muscle problems</u></p><p>Contact your doctor, pharmacist or nurse immediately if you experience unexplained muscle pain, tenderness, or weakness while taking this medicine.</p><p>&nbsp;</p><p><u>Skin problems</u></p><p>Contact your doctor promptly if you develop a rash. Severe and life-threatening skin reactions and allergic reactions have been reported in some patients taking this medicine.</p><p>&nbsp;</p><p><strong>Other medicines and Isentress</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Isentress might interact with other medicines. Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antacids (an agent that counteracts or neutralises the acid in the stomach to relieve indigestion and heartburn)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iron salts (to treat and prevent iron deficiency or anemia). You should wait at least two hours between taking iron salts and taking Isentress, as these medicines may reduce Isentress efficacy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atazanavir (an antiretroviral medication)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (a medicine used to treat some infections such as tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tipranavir/ritonavir (antiretroviral medicines)</p><p>&nbsp;</p><p>Keep a list of all your medicines to show your doctor and pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can ask your doctor or pharmacist for a list of medicines that interact with Isentress.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not start taking a new medicine without telling your doctor. Your doctor can tell you if it is safe to take Isentress with other medicines.</p><p>&nbsp;</p><p><strong>Taking Isentress with food and drink</strong></p><p>See section&nbsp;3.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Isentress 1,200&nbsp;mg (two 600&nbsp;mg tablets once daily) is not recommended in pregnancy because it has not been studied in pregnant women.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</p><p>&nbsp;</p><p>Ask your doctor, pharmacist or nurse for advice before taking any medicine if you are pregnant or breast-feeding.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Do not operate machines, drive or cycle if you feel dizzy after taking this medicine.</p><p>&nbsp;</p><p><strong>Isentress contains lactose</strong></p><p>This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Isentress contains </strong><strong>sodium</strong></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.9pt; margin-right:3.05pt">Always take this medicine exactly as your doctor, pharmacist or nurse has told you. You should check with your doctor, pharmacist or nurse if you are not sure. Isentress must be used in combination with other medicines for HIV.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>How much to take</strong></p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>Adults, children and adolescents weighing at least 40 kg</strong></p><p style="margin-left:5.9pt; margin-right:-1.0pt">The recommended dose is 1,200 mg taken as two 600 mg tablets taken by mouth once a day.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:5.25pt">Do not chew, crush or split the tablets because it may change the level of medicine in your body. This medicine can be taken with or without food or drink.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:5.25pt">Isentress is also available in a 400 mg tablet. Do not switch between the 600 mg tablet and 400 mg tablet without first talking with your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>I</strong><strong>f you take more Isentress than you should</strong></p><p style="margin-left:5.9pt; margin-right:16.85pt">Do not take more tablets than the doctor recommends. If you do take too many tablets, contact your doctor.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>I</strong><strong>f you forget to take Isentress</strong></p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, take it as soon as you remember it.</p><p style="margin-left:34.25pt; margin-right:29.7pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, if it is time for your next dose, skip the missed dose and go back to your regular schedule.</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>I</strong><strong>f you stop taking Isentress</strong></p><p style="margin-left:5.9pt; margin-right:7.7pt">It is important that you take Isentress exactly as your doctor has instructed. Do not change the dose or stop taking this medicine without first talking with your doctor, pharmacist or nurse.</p><p style="margin-left:5.9pt; margin-right:-1.0pt">Do not stop taking it because:</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important to take all your HIV medicines as prescribed and at the right times of day.</p><p style="margin-left:34.25pt; margin-right:20.65pt">This can help your medicines work better. It also lowers the chance that your medicines will stop being able to fight HIV (also called &quot;drug resistance&quot;).</p><p style="margin-left:34.25pt; margin-right:2.8pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When your supply of Isentress starts to run low, get more from your doctor or pharmacy. This is because it is very important not to be without the medicine, even for a short time. During a short</p><p style="margin-left:34.25pt; margin-right:-1.0pt">break in taking the medicine the amount of virus in your blood may increase. This may mean</p><p style="margin-left:34.25pt; margin-right:-1.0pt">that the HIV virus will develop resistance to Isentress and become harder to treat.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.9pt; margin-right:-1.0pt">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>Serious side effects </strong>&ndash; these are uncommon (may affect up to 1 in 100 people)</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>See a doctor immediately, if you notice any of the following:</strong></p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes infections including shingles</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia including due to low iron</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs and symptoms of infection or inflammation</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mental disorder</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicide intention or attempt</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach inflammation</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of liver</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic rash</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain kinds of kidney problems</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drug ingestion in quantities greater than recommended</p><p style="margin-left:5.9pt; margin-right:151.0pt">See a doctor immediately, if you notice any of the side effects above. Common: the following may affect up to 1 in 10 people</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p style="margin-left:34.25pt; margin-right:17.6pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping; abnormal dreams; nightmare; abnormal behaviour; feelings of deep sadness and unworthiness</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy; headache</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating; abdominal pain; diarrhoea; excessive gas in the stomach or bowel; feeling sick;</p><p style="margin-left:34.25pt; margin-right:-1.0pt">vomiting; indigestion; belching</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain kinds of rash (more often when used in combination with darunavir)</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, unusual tiredness or weakness; fever</p><p>&nbsp;</p><p style="margin-left:34.25pt; margin-right:11.55pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased liver blood tests; abnormal white blood cells; increased fat levels in blood; increased level of enzyme from salivary glands or pancreas</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">Uncommon: the following may affect up to 1 in 100 people</p><p style="margin-left:34.25pt; margin-right:3.9pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the hair roots; influenza; skin infection due to virus; vomiting or diarrhoea due to an infectious agent; upper respiratory tract infection; lymph node abscess</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wart</p><p style="margin-left:34.25pt; margin-right:4.9pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lymph node pain; low count of white blood cells that fight infection; swollen glands in the neck, armpit and groin</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction;</p><p style="margin-left:34.25pt; margin-right:27.05pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased appetite; diabetes; increased blood cholesterol and lipids; high sugar levels in the blood; excessive thirst; severe weight loss; high levels of fat (such as cholesterol and triglycerides) in the blood; body fat disorder</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious; feeling of confusion; depressed mood; mood changes; panic attack</p><p style="margin-left:34.25pt; margin-right:12.35pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of memory; pain in the hand due to nerve compression; disturbance in attention; dizziness with rapid changes in posture; abnormal taste; increased sleepiness; lack of energy; forgetfulness; migraine headache; loss of feeling, numbness or weakness of the arms and/or</p><p style="margin-left:34.25pt; margin-right:-1.0pt">legs; tingling; sleepiness; tension headache; tremors; poor quality sleep</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbance</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; buzzing, hissing, whistling, ringing or other persistent noise in the ears</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations; slow heart rates; fast or irregular heart beats</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush; high blood pressure</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; harsh, raspy, or strained voice; nosebleed; nasal congestion</p><p style="margin-left:34.25pt; margin-right:7.9pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain upper; rectal discomfort; constipation; dry mouth; heartburn; pain when swallowing; inflammation of the pancreas; ulcer or sore in stomach or upper intestine; bleeding at anus; stomach discomfort; inflammation of the gums; swollen, red sore tongue</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of fat in the liver</p><p style="margin-left:34.25pt; margin-right:9.1pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne; unusual hair loss or thinning; redness of skin; unusual distribution of fat on the body, this may include loss of fat from legs, arms, and face, and increase in abdomen fat; excessive sweating; night sweats; thickening and itching of the skin due to repeated scratching; skin</p><p style="margin-left:34.25pt; margin-right:-1.0pt">lesion; dry skin</p><p style="margin-left:34.25pt; margin-right:3.0pt; text-align:justify; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain; painful joint disease; back pain; pain in bone/muscle; muscle tenderness or weakness; neck pain; pain in arms or legs; inflammation of the tendons; decrease in the amount of minerals in the bone</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney stones; urination at night; kidney cyst</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erectile dysfunction; breast enlargement in men; menopausal symptoms</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort; chills; swelling of face; feeling jittery; generally feeling unwell; neck mass;</p><p style="margin-left:34.25pt; margin-right:-1.0pt">swelling of hands, ankles or feet; pain</p><p style="margin-left:34.25pt; margin-right:7.65pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased white blood cell count; decreased count of platelets in blood (a kind of cell that helps blood clot); blood test showing reduced kidney function; high blood sugar level; increased muscle enzyme in blood; sugar present in urine; red blood cells present in urine; weight gain; increase in waist size; decreased blood protein (albumin); increase in time for blood to clot</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">Additional side effects in children and adolescents</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>Reporting of side effects</strong></p><p style="margin-left:5.9pt; margin-right:20.55pt">If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p style="margin-left:34.25pt; margin-right:27.65pt; text-indent:-28.3pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date is written on outer carton &amp; inner label.</p><p style="margin-left:5.9pt; margin-right:60.05pt; text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Keep the bottle tightly closed, with the desiccant in order to protect from moisture.</p><p style="margin-left:5.9pt; margin-right:60.05pt; text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:14.5pt">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.9pt; margin-right:339.15pt; text-align:justify"><strong>What Isentress contains</strong></p><p style="margin-left:5.9pt; margin-right:41.65pt; text-align:justify">The active substance is raltegravir. Each film-coated tablet contains 600 mg of raltegravir (as</p><p style="margin-left:5.9pt; margin-right:400.7pt; text-align:justify">potassium).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:5.05pt; text-align:justify">The other ingredients are: microcrystalline cellulose, hypromellose 2910, croscarmellose sodium and magnesium stearate. In addition, the film coating contains the following inactive ingredients: lactose monohydrate, hypromellose 2910, titanium dioxide, triacetin, iron oxide yellow and black iron oxide. The tablet may also contain trace amount of carnauba wax.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 600 mg film-coated tablet is oval-shaped, yellow, marked with Merck logo and "242" on one side and plain on the other side.

One pack size is available: 1 bottle with 60 tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.9pt; margin-right:-3.65pt"><strong>Marketing Authorization Holder :</strong></p><p style="margin-left:5.9pt; margin-right:325.35pt">Merck Sharp &amp; Dohme Ltd, 120 Moorgate, London, EC2M 6UR, United Kingdom</p><p style="margin-left:5.9pt; margin-right:-1.0pt">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>Manufacturer:</strong></p><p style="margin-left:5.9pt; margin-right:325.35pt">MSD International GmbH (Singapore Branch), 70 Tuas West Drive, Singapore</p><p style="margin-left:5.9pt; margin-right:-3.65pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	
This leaflet was last revised in October 2022.



  To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
•	Other GCC States: 
Please contact the relevant competent authority.
This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health Ministers 
Union of Arab Pharmacists
This patient information leaflet is approved by the Saudi Food and Drug Authority



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right"><strong>ما هو أيزينتريس</strong><br />يحتوي أيزينتريس على المادة الفعالة رالتيجرافير . أيزينتريس هو دواء مضاد للفيروسات يعمل ضد فيروس نقص المناعة البشرية (إش أي في HIV). وهو الفيروس الذي يسبب متلازمة نقص المناعة المكتسبة (الإيدز).</p><p dir="RTL" style="text-align:right"><strong>آلية عمل أيزينتريس </strong><br />يُنتج الفيروس إنزيما يدعى إنزيم نقص المناعة البشرية المدمج.وهذا الإنزيم هو الذي يساعد الفيروس على التكاثر داخل خلايا الجسم. أيزينتريس يوقف عمل هذا الانزيم. وعند استخدامه مع أدوية أخرى، قد يقلل أيزينتريس من كمية فيروس نقص المناعة البشرية في دمك (وهذا ما يسمى &quot;الحِمل الفيروسي&quot;) كما يزيد عدد خلايا كتلة التمايز 4 &nbsp;(نوع من خلايا الدم البيضاء التي تلعب دورا هاما في الحفاظ على نظام المناعة الصحي للمساعدة في مكافحة العدوى). قد يؤدي خفض كمية فيروس نقص المناعة البشرية في الدم إلى تحسين أداء الجهاز المناعي. وهذا يعني أن جسمك قد يحارب العدوى بشكل أفضل.</p><p dir="RTL" style="text-align:right"><strong>متى ينبغي استخدام</strong> <strong>أيزينتريس </strong><br />تُستخدم أقراص أيزينتريس 600 ملغم المغلفة في علاج البالغين والأطفال ممن تبلغ أوزانهم 40 كلغم على الأقل المصابين بعدوى فيروس نقص المناعة البشرية. وقد وصف لك طبيبك أيزينتريس للمساعدة في السيطرة على عدوى فيروس نقص المناعة البشرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أيزينتريس </strong><br />* إذا كانت لديك حساسية نحو رالتيجرافير أو نحو أيّ من المكونات الأخرى في هذا الدواء (المدرجة في الفقرة رقم 6)&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong><br />تحدث مع طبيبك أو الصيدلي أو الممرض قبل تناول أيزينتريس.<br />تذكر أن أيزينتريس لا يَشفي من عدوى فيروس المناعة البشرية. وهذا يعني أنك قد تستمر في التعرض للالتهابات أو غيرها من الأمراض المرتبطة بفيروس نقص المناعة البشرية. يجب أن تستمر في مراجعة الطبيب بانتظام أثناء تناول هذا الدواء.</p><p dir="RTL"><u>مشاكل نفسيّة</u><br />أخبر طبيبك إذا كان لديك تاريخ من الإصابة بالاكتئاب أو أي مرض نفسي. هناك تقارير عن حدوث الاكتئاب، بما في ذلك الأفكار والسلوكيات الانتحارية، لدى بعض المرضى الذين يتناولون هذا الدواء، وخاصة أولئك الذين عانوا من تاريخ سابق من الاكتئاب أو المرض النفسي.</p><p dir="RTL"><u>مشاكل العظام</u><br />قد يتعرض بعض المرضى الذين يتناولون مزيج من مضادات الفيروسات الرجعية لمرض في العظام يُسمّى تنخّر العظم (موت الأنسجة العظمية الناجم عن عدم وصول الدم إلى العظام). هناك عوامل خطورة كثيرة يمكن أن تساهم في حدوث هذا المرض منها المدة الزمنية التي تم خلالها تناول مزيج مضادات الفيروسات الرجعية، واستخدام الكورتيزون، واستهلاك الكحول، والتدني الشديد في نشاط الجهاز المناعي، وارتفاع مؤشر كتلة الجسم. علامات تنخر العظم هي تيبُّس المفاصل، وآلام وأوجاع (وخاصة في الورك والركبة والكتف) وصعوبة في الحركة. إذا لاحظت أي من هذه الأعراض يرجى إبلاغ الطبيب.</p><p dir="RTL"><u>مشاكل الكبد</u><br />أخبر طبيبك أو الصيدلي أو الممرض إذا سبق وعانيت من مشاكل في الكبد، بما في ذلك التهاب الكبد ب أو ج. قد يقوم طبيبك بتقييم مدى خطورة مرض الكبد لديك قبل أن يُقرر ما إذا كان بإمكانك تناول هذا الدواء.</p><p dir="RTL"><u>الالتهابات الجرثومية </u><br />أخبر طبيبك أو الصيدلي أو الممرض فورا إذا لاحظت أي أعراض للعدوى، مثل الحمى، و / أو الشعور بالتوعّك. قد تظهر لدى بعض المرضى المصابين بعدوى متقدمة من فيروس نقص المناعة البشرية وتاريخ العدوى الانتهازية، علامات وأعراض التهاب من عدوى سابقة، بعد وقت قصير من بدء العلاج بمضادات &nbsp;فيروس نقص المناعة البشرية. ويعتقد أن هذه الأعراض هي نتيجة لتحسن الاستجابة المناعية للجسم، مما يُمَكن الجسم من مكافحة العدوى التي قد تكون موجودة دون وجود أعراض واضحة.</p><p dir="RTL">بالإضافة إلى العدوى الانتهازية، قد تحدث اضطرابات المناعة الذاتية (وهي حالة تحدث عندما يهاجم الجهاز المناعي أنسجة الجسم السليمة) بعد البدء في تناول الأدوية التي تُستخدم في علاج عدوى فيروس نقص المناعة البشرية. قد تحدث اضطرابات المناعة الذاتية بعد عدة أشهر من بدء العلاج. إذا لاحظت أي أعراض للعدوى أو أعراض أخرى مثل ضعف العضلات والضعف الذي يبدأ من اليدين والقدمين وينتقل نحو جذع الجسم، والخفقان، والرعاش أو فرط النشاط، يرجى إبلاغ الطبيب فورا للحصول على العلاج اللازم.</p><p dir="RTL"><u>مشاكل العضلات</u><br />اتصل بطبيبك أو الصيدلي أو الممرض على الفور إذا تعرضت لألم عضلي مجهول السبب أو ألم عند لمس المنطقة المُتأثرة أو ضعف أثناء تناول هذا الدواء.</p><p dir="RTL"><u>مشاكل جلديّة </u></p><p dir="RTL">راجع الطبيب على الفور إذا تعرّضت لطفح جلدي. هناك تقارير عن ردود فعل جلدية شديدة ومهددة للحياة وردود فعل تحسسية لدى بعض المرضى ممن تناولوا هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى و أيزينتريس </strong><br />أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول، تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد يتداخل أيزينتريس<strong> </strong>مع أدوية أخرى. أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول، قد تناولت &nbsp;مؤخرا أو قد تتناول:<br />&bull; مضادات الحموضة (الأدوية التي تعاكس أو تعادل حمض المعدة لتخفيف عسر الهضم والحرقة)<br />&bull; أتازانافير (دواء مضاد للفيروسات الرجعية)</p><p>Arabic translation.&nbsp;</p><p dir="RTL">&bull; أملاح الحديد (لعلاج ومنع نقص الحديد أو فقر الدم). &nbsp;يجب الانتظار ساعتين على الأقل بين تناول أملاح الحديد و أملاح أيزينتريس ، لأن هذه الأدوية قد تقلل من فعالية أيزينتريس</p><p dir="RTL">&bull; ريفامبيسين (دواء يستخدم في علاج بعض أنواع العدوى مثل السل)<br />&bull; تيبرانافير / ريتونافير (الأدوية المضادة للفيروسات الرجعية)</p><p dir="RTL">احتفظ بأسماء جميع أدويتك في قائمة لتعرضها على الطبيب والصيدلي.<br />&bull; يمكنك أن تطلب من طبيبك أو الصيدلي الحصول على قائمة الأدوية التي تتداخل مع أيزينتريس .<br />&bull; لا تبدأ في تناول دواء جديد دون إخبار طبيبك. یمکن لطبیبك أن یخبرك إذا کان من الآمن تناول أيزينتريس مع الأدویة الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أيزينتريس مع الطعام والشراب</strong><br />انظر الفقرة رقم 3.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حامل أو مرضعة، تعتقدين أنك قد تكون حامل أو تخططين للحمل.<br />&bull; لا يُنصح باستخدام أيزينتريس 1,200 ملغ (قرصان 600 ملغ مرة واحدة يوميا)<strong> </strong>أثناء الحمل لأنه لم يتم دراسته لدى النساء الحوامل.<br />&bull; لا يُنصح بالرضاعة الطبيعية عند النساء المصابات بفيروس نقص المناعة البشرية بسبب احتمال إصابة الأطفال بفيروس نقص المناعة البشرية من خلال حليب الأم.</p><p dir="RTL">&bull; إذا كنت ترضعين طفلك رضاعة طبيعية، أو تفكرين في الرضاعة الطبيعية، فيجب عليك مناقشة الأمر مع طبيبك في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;استشيري طبيبك أو الصيدلي أو الممرض قبل تناول أي دواء إذا كنت حامل أو مرضعة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />لا تقم بتشغيل الآلات أو بقيادة السيارة أو بركوب الدراجة إذا شعرت بالدوار بعد تناول هذا الدواء.</p><p dir="RTL"><strong>يحتوي أيزينتريس على اللاكتوز</strong><br />هذا الدواء يحتوي على اللاكتوز. إذا كان طبيبك قد أخبرك أن لديك عدم تحمل لبعض السكريات، فتحدث إلى الطبيب قبل تناول هذا الدواء.</p><p dir="RTL"><strong>يحتوي أيزينتريس على الصوديوم</strong></p><p dir="RTL">هذا الدواء يحتوي على أقل من 1 مليمول الصوديوم (23 ملغ) لكل قرص، وهذا يعني أساسا &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">تناول هذا الدواء دائما حسب ارشادات الطبيب أو الصيدلي أو الممرض تمامًا. يجب عليك مراجعة الطبيب أو الصيدلي أو الممرض إذا لم تكن متأكدا. يجب استخدام أيزينتريس مع الأدوية الأخرى التي تعالج عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL" style="text-align:right"><strong>الجرعة التي ينبغي تناولها<br />البالغين، الأطفال والمراهقين ممن تبلغ أوزانهم 40 كلغم على الأقل</strong><br />الجرعة الموصى بها هي 1200 ملغم تؤخذ على شكل قرصين من أقراص 600 ملغم مرة واحدة في اليوم عن طريق الفم.<br />لا تمضغ، تسحق أو تُقسّم الأقراص لأن ذلك قد يُغير مستوى الدواء في جسمك. يمكن تناول هذا الدواء مع أو بدون طعام أو شراب.</p><p dir="RTL" style="text-align:right">يتوفر أيزينتريس أيضا على شكل أقراص تركيزها 400 ملغم. لا تقم بالتبديل بين قرص 600 ملغم ، قرص 400 ملغم دون التحدث أولا مع الطبيب أو الصيدلي أو الممرض.</p><p dir="RTL" style="text-align:right"><strong>إذا تناولت من أيزينتريس أكثر مما يجب</strong><br />لا تتناول من الأقراص أكثر مما وصفه لك الطبيب. إذا تناولت جرعة مفرطة، اتصل بطبيبك.</p><p dir="RTL" style="text-align:right"><strong>إذا نسيت أن تتناول إحدى جرعات أيزينتريس </strong><br />&bull; إذا نسيت تناول جرعة، فتناولها حالما تتذكرها.<br />&bull; ولكن، إذا تذكرتها في وقت الجرعة التالية، تخطى الجرعة الفائتة ثم استمر في الالتزام بالجدول الزمني الخاص بك كالمعتاد.<br />&bull; لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL" style="text-align:right"><strong>إذا توقفت عن تناول أيزينتريس </strong><br />من المهم أن تتناول أيزينتريس<strong> </strong>حسب ارشادات الطبيب تمامًا. لا تُغير الجرعة أو تتوقف عن تناول هذا الدواء دون التحدث أولا مع طبيبك أو الصيدلي أو الممرض.<br />لا تتوقف عن تناوله لأنه:<br />&bull; من المهم جدا تناول جميع أدوية علاج فيروس نقص المناعة البشرية الخاصة بك كما هو محدد وفي الوقت المناسب من اليوم. يمكن أن يساعد ذلك على أن تعمل أدويتك بشكل أفضل. كما أنه يقلل من احتمال أن تصبح الأدوية الخاصة بك غير قادرة على مكافحة فيروس نقص المناعة البشرية (ما يُسمى أيضا &quot;مقاومة الدواء&quot;).<br />&bull; عندما يقل مخزون الدواء لديك، احصل على المزيد من خلال طبيبك أو الصيدلية. وذلك لأنه من المهم جدا ألا تنقطع عن الدواء، حتى لفترة قصيرة. لأن التوقف عن تناول الدواء حتى لفترة قصيرة قد يؤدي إلى زيادة كمية الفيروس في دمك. وهذا قد يعني أن فيروس نقص المناعة البشرية سوف يصبح مقاوماً للعلاج بأيزينتريس وبالتالي يُصبح من الصعب علاجه.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">يمكن أن يسبب تناول هذا الدواء أعراض جانبية، كما هو الحال مع سائر الأدوية، وإن كانت لا تحدث لدى جميع من يتناوله.<br /><strong>الأعراض الجانبية الخطيرة -</strong> وهذه غير شائعة (قد تؤثر على ما يصل إلى 1 من 100 شخص)<br /><strong>راجع الطبيب فورا، إذا لاحظت أي مما يلي:</strong><br />&bull; التهابات الهربس بما في ذلك الهربس النّطاقي<br />&bull; فقر الدم بما في ذلك فقر الدم الناجم عن نقص الحديد<br />&bull; علامات وأعراض العدوى أو الالتهاب<br />&bull; اضطراب نفسي<br />&bull; نية الانتحار أو محاولة القيام به<br />&bull; التهاب المعدة<br />&bull; التهاب الكبد<br />&bull; تليف كبدى<br />&bull; الطفح الجلدي التحسسي<br />&bull; أنواع معينة من مشاكل الكلى<br />&bull; تناول أدوية بكميات أكبر من الموصى بها</p><p dir="RTL" style="text-align:right">راجع الطبيب فورا، إذا لاحظت أي من الأعراض الجانبية أعلاه.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong><u>شائعة:</u></strong><u> قد يؤثر ما يلي على ما يصل إلى 1 من كل 10 أشخاص</u><br />&bull; قلة الشهية<br />&bull; صعوبة في النوم؛ أحلام غير طبيعية. كوابيس؛ سلوك غير طبيعي؛ الشعور بالحزن العميق وعدم الجدارة<br />&bull; الشعور بالدوار؛ صداع الراس<br />&bull; الإحساس بالدوار<br />&bull; الانتفاخ؛ وجع في البطن؛ إسهال؛ الغاز المفرط في المعدة أو الأمعاء؛ الشعور بالمرض؛ التقيؤ؛ عسر<br />&nbsp; الهضم؛ التجشؤ<br />&bull; أنواع معينة من الطفح الجلدي (تحدث بتكرارية أكثر عند تناوله مع دارونافير)<br />&bull; التعب، التعب أو الضعف غير العاديين؛ حمّى<br />&bull; ارتفاع في نتائج تحاليل وظائف الكبد؛ كريات الدم البيضاء غير طبيعية؛ ارتفاع مستوى الدهون في الدم؛<br />&nbsp; ارتفاع مستوى الإنزيم في اللعاب والبنكرياس.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><u>غير شائعة: قد يؤثر ما يلي على ما يصل إلى 1 من بين 100 شخص</u><br />&bull; التهاب جذور الشعر؛ الإنفلونزا؛ عدوى الجلد بسبب الفيروس؛ والقيء أو الإسهال بسبب عامل معدي؛<br />&nbsp;&nbsp;عدوى الجهاز التنفسي العلوي؛ خراج العقدة الليمفاوية<br />&bull; ظهور الثآليل<br />&bull; ألم في العُقد الليمفاوية؛ انخفاض عدد خلايا الدم البيضاء التي تحارب العدوى؛ تورم الغدد في الرقبة، الإبط<br />&nbsp; والفخذ<br />&bull; رد فعل تحسسي؛<br />&bull; زيادة الشهية؛ داء السكري؛ زيادة الكوليسترول والدهون في الدم؛ ارتفاع مستويات السكر في الدم؛ العطش<br />&nbsp; الشديد؛ فقدان الوزن الشديد؛ مستويات عالية من الدهون في الدم (مثل الكولسترول والدهون الثلاثية)؛<br />&nbsp; اضطراب الدهون في الجسم<br />&bull; الشعور بالقلق؛ الشعور بالارتباك؛ مزاج مُحبط؛ تغيرات في المزاج؛ نوبة الهلع<br />&bull; فقدان الذاكرة؛ ألم في اليد بسبب ضغط العصب؛ اضطراب في التركيز؛ والدوخة مع التغيرات السريعة في<br />&nbsp; الوضعيّة؛ طَعْم غير طبيعي؛ زيادة في النعاس؛ نقص الطاقة؛ النسيان؛ صداع نصفي؛ فقدان الإحساس<br />&nbsp; ، خدر أو ضعف في الذراعين و / أو الساقين؛ التنميل؛ النعاس؛ صداع التوتر؛ الارتعاش؛ جودة منخفضة<br />&nbsp; للنوم<br />&bull; اضطرابات بصرية<br />&bull; أزيز، هسيس، صفير، رنين أو غيرها من الضوضاء المستمرة في الأذنين<br />&bull; الخفقان؛ بطء معدل ضربات القلب؛ تسارع أو عدم انتظام ضربات القلب&nbsp;<br />&bull; الهبّات الساخنة؛ ارتفاع ضغط الدم<br />&bull; صوت خشن؛ أجشّ، أو مُجهَد؛ نزيف الأنف &quot;الرعاف&quot;؛ إحتقان بالأنف<br />&bull; آلام في الجزء العلوي من البطن؛ الشعور بالانزعاج في فتحة الشرج؛ الإمساك؛ جفاف الفم؛ حرقة في<br />&nbsp;&nbsp;المعدة؛ ألم أثناءالبلع؛ التهاب البنكرياس؛ قرحة أو التهاب في المعدة أو الجزء العلوي من الأمعاء؛ نزيف<br />&nbsp; في الشرج؛ الشعور بعدم الارتياح في البطن؛ التهاب اللثة؛ تورم، واحمرار واحتقان اللسان<br />&bull; تراكم الدهون في الكبد<br />&bull; حب الشباب؛ تساقط أو ترقق الشعر بشكل غير معتاد؛ احمرار الجلد؛ توزيع غير عادي للدهون في &nbsp;<br />&nbsp; الجسم، وهذا قد يشمل فقدان الدهون من الساقين والذراعين والوجه، وتراكم الدهون في البطن؛ التعرق<br />&nbsp; المفرط؛ تعرق ليلي؛ سماكة وحكة في الجلد بسبب الخدش الناجم عن الحكة المتكررة؛ آفات جلدية؛ جفاف الجلد<br />&bull; الم المفاصل؛ مرض مؤلم في المفاصل؛ ألم في الظهر؛ ألم في العظام / العضلات؛ ضعف العضلات أو<br />&nbsp; الشعور بالألم عند الضغط عليها؛ ألم في الرقبة؛ ألم في الذراعين أو الساقين؛ التهاب الأوتار؛ انخفاض في<br />&nbsp; كمية المعادن في العظام<br />&bull; حصى في الكلى؛ التبول في الليل؛ ظهور كيس في الكلى<br />&bull; ضعف الانتصاب؛ تضخّم الثدي لدى الرجال؛ أعراض انقطاع الطمث<br />&bull; الشعور بعدم الارتياح في الصدر؛ قشعريرة؛ تورم الوجه؛ الشعور بالارتباك؛ الشعور العام بالتوعك؛ كتلة في<br />&nbsp; الرقبة؛ تورم اليدين والكاحلين أو القدمين؛ ألم<br />&bull; انخفاض عدد خلايا الدم البيضاء؛ انخفاض عدد الصفائح الدموية في الدم (وهو نوع من الخلايا التي<br />&nbsp; تساعد على تجلط الدم)؛ تدني في وظائف الكلى كما يظهر في تحاليل الدم. ارتفاع مستوى السكر في<br />&nbsp; الدم؛ زيادة في مستوى انزيم العضلات في الدم؛ وجود سكر في البول؛ وجود خلايا دم في البول؛ زيادة<br />&nbsp;&nbsp;الوزن؛ زيادة في محيط الخصر؛ انخفاض في بروتين الدم (ألبومين)؛ زيادة في الزمن اللازم لتجلط الدم</p><p dir="RTL" style="text-align:right"><u>أعراض جانبية إضافية لدى الأطفال والمراهقين</u><br />&bull; فرط النشاط</p><p dir="RTL" style="text-align:right"><strong>الإبلاغ عن الأعراض الجانبيّة</strong><br />إذا تعرّضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي أو الممرض. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عن طريق المركز الوطني للتيقظ الدوائي والسلامة الدوائية ، التابع لهيئة الغذاء والدواء السعودية. يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء عن طريق الإبلاغ عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">&bull; يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال .<br />&bull; لا تستخدم الدواء بعد تاریخ انتهاء الصلاحیة المُدّون علی القارورة بعد EXP. تاريخ انتهاء مُدوّن على العلبة الخارجية والملصق الداخلي.<br />&bull; يُرجى إغلاق العبوة بإحكام لحمايتها من الرطوبة .<br />&bull; يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. وستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ماذا يحتوي أيزينتريس </strong><br />المادة الفعالة هي رالتيجرافير . يحتوي كل قرص مغلف بغشاء رقيق على 600 ملغم من رالتيجرافير (على هيئة ملح البوتاسيوم).</p><p dir="RTL" style="text-align:right">المكونات الأخرى هي: السليلوز دقيق التبلور، هيبروميلوز 2910، كروسكارملوس الصوديوم و ستيرات المغنيسيوم. وبالإضافة إلى ذلك، تحتوي طبقة الغشاء المُغلف للقرص على المكونات غير النشطة التالية: لاكتوز مونوهيدرات ، هيبروميلوز 2910، ثاني أكسيد التيتانيوم، ترياسيتين، أكسيد الحديد الأصفر وأكسيد الحديد الأسود. قد يحتوي على قرص أيضا كمية ضئيلة من شمع كرنوبا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">قرص أيزينتريس 600 ملغم المغلف بغشاء رقيق &nbsp;شكله بيضاوي، أصفر اللون، مطبوع على جانب واحد منه فقط شعار ميرك و &quot;242&quot; .</p><p dir="RTL" style="text-align:right">تتوفر علب أيزينتريس في حجم واحد: قارورة واحدة تحتوي على 60 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>الشركة المالكة لحقوق التسويق </strong></p><p dir="RTL" style="text-align:right"><strong>:</strong>ميرك شارب آند دوهم المحدودة، 120 مورجيت، لندن، إي سي 2 إم 6 يو آر ، المملكة المتحدة</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الشركة المصنعة: </strong><br />إم إس دي إنترناشيونال جي إم بي إتش (فرع سنغافورة)، ٧٠ تواس ويست دريف ،سنغافورة</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ أكتوبر 2022







للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.

(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحه العرب
و اتحاد الصيادلة العرب

تمت الموافقة على نشرة المعلومات هذه للمريض من قبل الهيئة العامة الغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Isentress 600 mg film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 600 mg of raltegravir (as potassium). Excipient with known effect
Each 600 mg tablet contains 5.72 mg lactose (as monohydrate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Film-coated tablet.

Yellow, oval-shaped, dimensions 19.1 mm x 9.7 mm x 6.1 mm, marked with Merck logo and “242”
on one side and plain on the other side.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:17.95pt">Isentress 600 mg film-coated tablets is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, and paediatric patients weighing at least 40 kg (see sections 4.2, 4.4, 5.1 and 5.2).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection. <u>Posology</u></p><p>ISENTRESS should be used in combination with other active anti-retroviral therapies (ARTs) (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><em>Adults and paediatric population</em></p><p>In adults and paediatric patients (weighing at least 40 kg), the recommended dosage is 1,200 mg (two 600 mg tablets) once daily for treatment-na&iuml;ve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily.</p><p>&nbsp;</p><p>Additional formulations and strengths available:</p><p>ISENTRESS is also available as a 400 mg tablet for twice daily use in HIV infected adults or children and adolescents at least 25 kg. The 400 mg tablet should not be used to administer 1,200 mg once daily regimen (please refer to the 400 mg Summary of Product Characteristics).</p><p>&nbsp;</p><p>ISENTRESS is also available in a chewable tablet formulation and in granules for oral suspension formulation. Refer to the chewable tablet and granules for oral suspension SmPCs for additional dosing information.</p><p>The safety and efficacy of raltegravir in preterm (&lt;37 weeks of gestation) and low birth weight (&lt;2,000 g) newborns have not been established. No data are available in this population and no dosing recommendations can be made.</p><p>&nbsp;</p><p>The maximum dose of the chewable tablet is 300 mg twice daily. Because the formulations have different pharmacokinetic profiles neither the chewable tablets nor the granules for oral suspension should be substituted for the 400 mg tablet or the 600 mg tablet (see section 5.2). The chewable tablets and the granules for oral suspension have not been studied in HIV-infected adolescents (12 to</p><p>18 years) or adults.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>There is limited information regarding the use of raltegravir in the elderly (see section 5.2). Therefore, ISENTRESS should be used with caution in this population.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required for patients with renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is required for patients with mild to moderate hepatic impairment. The safety and efficacy of raltegravir have not been established in patients with severe underlying liver disorders. Therefore, ISENTRESS should be used with caution in patients with severe hepatic impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>ISENTRESS 600 mg film-coated tablet formulation should not be used in children weighing less than 40 kg.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p><p>ISENTRESS 600 mg tablets can be administered with or without food as a 1,200 mg once daily dose. The tablets should not be chewed, crushed or split due to anticipated changes in the pharmacokinetic profile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>Patients should be advised that current anti-retroviral therapy does not cure HIV and has not been proven to prevent the transmission of HIV to others through blood contact.</p><p>&nbsp;</p><p>Raltegravir has a relatively low genetic barrier to resistance. Therefore, whenever possible, raltegravir should be administered with two other active ARTs to minimise the potential for virological failure and the development of resistance (see section&nbsp;5.1).</p><p>&nbsp;</p><p>In treatment-na&iuml;ve patients, the clinical study data on use of raltegravir are limited to use in combination with two nucleotide reverse transcriptase inhibitors (NRTIs) (emtricitabine and tenofovir disoproxil fumarate).</p><p>&nbsp;</p><p><u>Depression</u></p><p><u>&nbsp;</u></p><p>Depression, including suicidal ideation and behaviours, has been reported, particularly in patients with a pre‑existing history of depression or psychiatric illness. Caution should be used in patients with a pre-existing history of depression or psychiatric illness.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of raltegravir have not been established in patients with severe underlying liver disorders. Therefore, raltegravir should be used with caution in patients with severe hepatic impairment (see sections&nbsp;4.2 and 5.2).</p><p>&nbsp;</p><p>Patients with pre‑existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination anti-retroviral therapy and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment should be considered.</p><p>&nbsp;</p><p>Patients with chronic hepatitis&nbsp;B or C and treated with combination anti-retroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.</p><p>&nbsp;</p><p><u>Osteonecrosis</u></p><p>&nbsp;</p><p>Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long‑term exposure to combination anti-retroviral therapy. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><u>Immune reactivation syndrome</u></p><p><u>&nbsp;</u></p><p>In HIV-infected patients with severe immune deficiency at the time of institution of combination anti-retroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by <em>Pneumocystis jiroveci </em>(formerly known as <em>Pneumocystis carinii</em>). Any inflammatory symptoms should be evaluated and treatment instituted when necessary<em>.</em></p><p>&nbsp;</p><p>Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation: however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>&nbsp;</p><p><u>Atazanavir</u></p><p><u>&nbsp;</u></p><p>Co-administration of raltegravir 1,200&nbsp;mg once daily with atazanavir resulted in increased raltegravir plasma levels; therefore, co-administration is not recommended (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Tipranavir/ritonavir</u></p><p><u>&nbsp;</u></p><p>Co-administration of raltegravir 1,200&nbsp;mg once daily with tipranavir/ritonavir could result in decreased raltegravir trough plasma levels; therefore, co‑administration is not recommended (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Antacids</u></p><p><u>&nbsp;</u></p><p>Co-administration of raltegravir 1,200&nbsp;mg once daily with calcium carbonate and aluminium/magnesium containing antacids resulted in reduced raltegravir plasma levels; therefore, co‑administration is not recommended (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Strong inducers of drug metabolizing enzymes</u></p><p><u>&nbsp;</u></p><p>Strong inducers of drug metabolizing enzymes (e.g., rifampicin) have not been studied with raltegravir 1,200&nbsp;mg once daily, but could result in decreased raltegravir trough plasma levels; therefore, co‑administration with raltegravir 1,200&nbsp;mg once daily is not recommended.</p><p>&nbsp;</p><p><u>Myopathy and rhabdomyolysis</u></p><p>&nbsp;</p><p>Myopathy and rhabdomyolysis have been reported. Use with caution in patients who have had myopathy or rhabdomyolysis in the past or have any predisposing issues including other medicinal products associated with these conditions (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Severe skin and hypersensitivity reactions</u></p><p>&nbsp;</p><p>Severe, potentially life-threatening, and fatal skin reactions have been reported in patients taking raltegravir, in most cases concomitantly with other medicinal products associated with these reactions. These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hypersensitivity reactions have also been reported and were characterised by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure. Discontinue raltegravir and other suspect agents immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, hepatitis, eosinophilia, angioedema). Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Delay in stopping raltegravir treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction.</p><p><u>&nbsp;</u></p><p><u>Rash</u></p><p><u>&nbsp;</u></p><p>Rash occurred more commonly in treatment-experienced patients receiving regimens containing raltegravir and darunavir compared to patients receiving raltegravir without darunavir or darunavir without raltegravir (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Lactose</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em>, raltegravir is a weak inhibitor of organic anion transporter (OAT) 1 (IC50 of 109 &micro;M) and&nbsp;OAT3&nbsp;(IC50 of 18.8 &micro;M). Caution is recommended when co-administering raltegravir 1,200 mg once daily with sensitive OAT1 and/or OAT3 substrates.</p><p>&nbsp;</p><p><em>In vitro </em>studies indicate that raltegravir is not a substrate of cytochrome P450 (CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not inhibit UDP glucuronosyltransferases (UGTs) 1A1 and 2B7, does not induce CYP3A4 and is not an inhibitor of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion-transporting polypeptides (OATP) 1B1, OATP1B3, organic cation transporters (OCT)1 and OCT2, or multidrug and toxin extrusion proteins (MATE)1 and MATE2-K. Based on these data, raltegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of these enzymes or transporters.</p><p>&nbsp;</p><p>Based on <em>in vitro </em>and <em>in vivo </em>studies, raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated glucuronidation pathway.</p><p>&nbsp;</p><p>Considerable inter- and intra-individual variability was observed in the pharmacokinetics of raltegravir.</p><p>&nbsp;</p><p><u>Effect of raltegravir on the pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p>In drug interaction studies performed using raltegravir 400 mg twice daily, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of etravirine, maraviroc, tenofovir disoproxil fumarate, hormonal contraceptives, methadone, midazolam or boceprevir. These findings can be extended to raltegravir 1,200 mg once daily and no dosage adjustment is required for these agents.</p><p>&nbsp;</p><p>In some studies, co-administration of raltegravir 400 mg tablets twice daily with darunavir resulted in a modest but clinically insignificant decrease in darunavir plasma concentrations. Based on the magnitude of effect seen with raltegravir 400 mg tablets twice daily, it is expected that the effect of raltegravir 1,200 mg once daily on darunavir plasma concentrations is likely to be not clinically meaningful.</p><p>&nbsp;</p><p><u>Effect of other medicinal products on the pharmacokinetics of raltegravir</u></p><p>&nbsp;</p><p><em>Inducers of drug metabolizing enzymes</em></p><p>The impact of medicinal products that are strong inducers of UGT1A1 such as rifampicin on raltegravir 1,200 mg once daily is unknown, but co-administration is likely to decrease raltegravir trough levels based on the reduction in trough concentrations observed with raltegravir 400 mg twice daily; therefore, co-administration with raltegravir 1,200 mg once daily is not recommended. The impact of other strong inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown; therefore, co-administration with raltegravir 1,200 mg once daily is not recommended. In drug interaction studies, efavirenz did not have a clinically meaningful effect on the pharmacokinetics of raltegravir 1,200 mg once daily; therefore, other less potent inducers (e.g., efavirenz, nevirapine, rifabutin, glucocorticoids, St. John&#39;s wort, pioglitazone) may be used with the recommended dose of raltegravir.</p><p>&nbsp;</p><p><em>Inhibitors of UGT1A1</em></p><p>Co-administration of atazanavir with raltegravir 1,200 mg once daily significantly increased plasma levels of raltegravir; therefore, co-administration of raltegravir 1,200 mg once daily and atazanavir is not recommended.</p><p>&nbsp;</p><p><em>Antacids</em></p><p>Co-administration of raltegravir 1,200 mg once daily with aluminium/magnesium and calcium carbonate containing antacids are likely to result in clinically meaningful reductions in the plasma trough levels of raltegravir. Based on these findings, co-administration of aluminium/magnesium and calcium carbonate containing antacids with raltegravir 1,200 mg once daily is not recommended.</p><p>&nbsp;</p><p><em>Agents that increase gastric pH</em></p><p>Population pharmacokinetic analysis from ONCEMRK (Protocol 292) showed that co-administration of raltegravir 1,200 mg once daily with PPIs or H2 blockers did not result in statistically significant changes in the pharmacokinetics of raltegravir. Comparable efficacy and safety results were obtained in the absence or presence of these gastric pH-altering agents. Based on these data, proton pump inhibitors and H2 blockers may be co-administered with raltegravir 1,200 mg once daily.</p><p>&nbsp;</p><p><em>Additional considerations</em></p><p>No studies have been conducted to evaluate the drug interactions of ritonavir, tipranavir/ritonavir, boceprevir or etravirine with raltegravir 1,200 mg (2 x 600 mg) once daily. While the magnitudes of change on raltegravir exposure from raltegravir 400 mg twice daily by ritonavir, boceprevir or etravirine were small, the impact from tipranavir/ritonavir was greater (GMR Ctrough=0.45, GMR&nbsp;AUC=0.76). Co-administration of raltegravir 1,200 mg once daily and tipranavir/ritonavir is not recommended.</p><p>&nbsp;</p><p>Previous studies of raltegravir 400 mg twice daily showed that co-administration of tenofovir disoproxil fumarate (a component of emtricitabine/tenofovir disaproxil fumarate) increased raltegravir exposure. Emtricitabine/tenofovir disaproxil fumarate was identified to increase raltegravir 1,200 mg</p><p>&nbsp;</p><p>once daily bioavailability by 12%, however its impact is not clinically meaningful. Therefore, co- administration of emtricitabine/tenofovir disaproxil fumarate and raltegravir 1,200 mg once daily is permitted.</p><p>&nbsp;</p><p>All interaction studies were performed in adults.</p><p>Comprehensive drug interaction studies were performed with raltegravir 400 mg twice daily and a limited number of drug interaction studies were performed for raltegravir 1,200 mg once daily.</p><p>&nbsp;</p><p>Table 1 displays all available interaction study data along with recommendations for co-administration.</p><p>&nbsp;</p><p><strong>Table 1</strong></p><p><strong>Pharmacokinetic Interaction Data</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal</strong><strong> </strong><strong>products by therapeutic </strong><strong>area</strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p>(mechanism, if known)</p></td><td style="vertical-align:top"><p><strong>Recommendations</strong><strong> </strong><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTI-RETROVIRAL</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Protease</em><em> </em><em>inhibitors</em><em> </em><em>(PI)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>atazanavir</strong><strong> </strong><strong>/ritonavir</strong></p></td><td style="vertical-align:top"><p>raltegravir AUC &shy; 41%</p></td><td style="vertical-align:top"><p>No dose adjustment required</p></td></tr><tr><td style="vertical-align:top"><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir&nbsp;C12hr &shy;&nbsp;77%</p></td><td style="vertical-align:top"><p>for raltegravir (400 mg twice</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>raltegravir&nbsp;Cmax &shy;&nbsp;24%</p></td><td style="vertical-align:top"><p>daily).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 inhibition)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>atazanavir</strong></p></td><td style="vertical-align:top"><p>raltegravir AUC &shy; 67%</p></td><td style="vertical-align:top"><p>Co-administration of raltegravir</p></td></tr><tr><td style="vertical-align:top"><p>(raltegravir 1,200 mg single dose)</p></td><td style="vertical-align:top"><p>raltegravir&nbsp;C24hr &shy;&nbsp;26%</p></td><td style="vertical-align:top"><p>(1,200 mg once daily) is not</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>raltegravir Cmax &shy;&nbsp;16%</p></td><td style="vertical-align:top"><p>recommended.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 inhibition)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>tipranavir</strong><strong> </strong><strong>/ritonavir</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 24%</p><p>raltegravir&nbsp;C12hr &macr;&nbsp;55%</p><p>raltegravir&nbsp;Cmax &macr;&nbsp;18%</p></td><td style="vertical-align:top"><p>No dose adjustment required for raltegravir (400 mg twice daily).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 induction)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Extrapolated from 400 mg</p></td><td style="vertical-align:top"><p>Co-administration of raltegravir</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>twice daily study</p></td><td style="vertical-align:top"><p>(1,200 mg once daily) is not</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>efavirenz</strong></p><p>(raltegravir 400 mg Single Dose)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 36% raltegravir&nbsp;C12hr &macr;&nbsp;21%</p><p>raltegravir&nbsp;Cmax &macr;&nbsp;36%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 induction)</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily).</p></td></tr><tr><td style="vertical-align:top"><p><strong>efavirenz</strong></p><p>(raltegravir 1,200 mg single dose)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 14% raltegravir&nbsp;C24hr &macr;&nbsp;6%</p><p>raltegravir&nbsp;Cmax &macr;&nbsp;9%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 induction)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>etravirine</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 10%</p><p>raltegravir&nbsp;C12hr &macr;&nbsp;34%</p><p>raltegravir&nbsp;Cmax &macr;&nbsp;11%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>No dose adjustment required</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 induction)</p></td><td style="vertical-align:top"><p>for raltegravir (400 mg twice</p><p>daily and 1,200 mg once daily)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>etravirine AUC &shy; 10% etravirine&nbsp;C12hr &shy;&nbsp;17%</p><p>etravirine Cmax &shy;&nbsp;4%</p></td><td style="vertical-align:top"><p>or etravirine.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal</strong><strong> </strong><strong>products by therapeutic </strong><strong>area</strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p>(mechanism, if known)</p></td><td style="vertical-align:top"><p><strong>Recommendations</strong><strong> </strong><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nucleoside/tide reverse transcriptase inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>tenofovir</strong><strong> </strong><strong>disoproxil</strong><strong> </strong><strong>fumarate</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &shy; 49% raltegravir C12hr &shy;&nbsp;3%&nbsp;raltegravir Cmax &uarr;&nbsp;64%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(mechanism of interaction unknown)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tenofovir AUC &macr; 10%</p><p>tenofovir&nbsp;C24hr &macr;&nbsp;13%&nbsp;tenofovir&nbsp;Cmax &darr;&nbsp;23%</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily) or tenofovir disoproxil fumarate.</p></td></tr><tr><td style="vertical-align:top"><p><strong>emtricitabine and tenofovir</strong><strong> </strong><strong>disoproxil</strong><strong> </strong><strong>fumarate</strong></p><p>(raltegravir 1,200 mg (2 x 600 mg) Once Daily)</p></td><td style="vertical-align:top"><p>Population PK analysis showed that the effect of emtricitabine/tenofovir disaproxil fumarate on raltegravir pharmacokinetics was minimal (12% increase in relative bioavailability), and was not statistically or clinically significant.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Mechanism of interaction unknown)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>CCR5 inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>maraviroc</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 37% raltegravir&nbsp;C12hr &macr;&nbsp;28%</p><p>raltegravir&nbsp;Cmax &macr;&nbsp;33%</p></td><td style="vertical-align:top"><p>No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily)</p><p>or maraviroc.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(mechanism of interaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>unknown)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>maraviroc AUC &macr; 14% maraviroc&nbsp;C12hr &macr;&nbsp;10%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>maraviroc&nbsp;Cmax &darr;&nbsp;21%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HCV</strong><strong> </strong><strong>ANTIVIRALS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>NS3/4A protease inhibitors (PI)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>boceprevir</strong></p><p>(raltegravir 400 mg Single Dose)</p></td><td style="vertical-align:top"><p>raltegravir AUC &shy; 4% raltegravir&nbsp;C12hr &macr;&nbsp;25%</p><p>raltegravir&nbsp;Cmax &shy;&nbsp;11%</p></td><td style="vertical-align:top"><p>No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily)</p><p>or boceprevir.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(mechanism of interaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>unknown)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIMICROBIALS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antimycobacterial</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>rifampicin</strong></p><p>(raltegravir 400 mg Single Dose)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 40%</p><p>raltegravir&nbsp;C12hr &macr;&nbsp;61%</p><p>raltegravir&nbsp;Cmax &macr;&nbsp;38%</p></td><td style="vertical-align:top"><p>Rifampicin reduces plasma levels of raltegravir. If</p><p>co-administration with</p><p>rifampicin is unavoidable, a</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 induction)</p></td><td style="vertical-align:top"><p>doubling of the dose of</p><p>raltegravir (400 mg twice daily)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>can be considered.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Extrapolated from 400 mg</p></td><td style="vertical-align:top"><p>Co-administration of raltegravir</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>twice daily study</p></td><td style="vertical-align:top"><p>(1,200 mg once daily) is not</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>recommended.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal</strong><strong> </strong><strong>products by therapeutic </strong><strong>area</strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p>(mechanism, if known)</p></td><td style="vertical-align:top"><p><strong>Recommendations</strong><strong> </strong><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>SEDATIVE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>midazolam</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>midazolam AUC &macr; 8% midazolam&nbsp;Cmax &uarr;&nbsp;3%</p></td><td style="vertical-align:top"><p>No dosage adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily) or midazolam.</p><p><strong>&nbsp;</strong></p><p>These results indicate that raltegravir is not an inducer or inhibitor of CYP3A4, and raltegravir is thus not anticipated to affect the pharmacokinetics of medicinal products which are CYP3A4</p><p>substrates.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>METAL</strong><strong> </strong><strong>CATION ANTACIDS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>aluminium</strong><strong> </strong><strong>and</strong><strong> </strong><strong>magnesium </strong><strong>hydroxide antacid</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 49% raltegravir C12 hr &macr;&nbsp;63% raltegravir Cmax &macr;&nbsp;44%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>2 hours before raltegravir</u> raltegravir AUC &macr; 51% raltegravir C12 hr &macr;&nbsp;56%&nbsp;raltegravir Cmax &macr;&nbsp;51%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>2 hours after raltegravir</u> raltegravir AUC &macr; 30% raltegravir C12 hr &macr;&nbsp;57%&nbsp;raltegravir&nbsp;Cmax &macr;&nbsp;24%</p><p><strong>&nbsp;</strong></p><p><u>6 hours before raltegravir</u> raltegravir AUC &macr; 13% raltegravir C12 hr &macr;&nbsp;50%&nbsp;raltegravir Cmax &macr;&nbsp;10%</p><p><strong>&nbsp;</strong></p><p><u>6 </u><u>hours after raltegravir</u> raltegravir AUC &macr; 11% raltegravir C12 hr &macr;&nbsp;49%&nbsp;raltegravir&nbsp;Cmax &macr;&nbsp;10%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Aluminium and magnesium containing antacids reduce raltegravir plasma levels.</p><p>Co-administration of raltegravir (400 mg twice daily and</p><p>1,200 mg once daily) with aluminium and/or magnesium containing antacids is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(chelation of metal cations)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>aluminium/magnesium hydroxide</strong><strong> </strong><strong>antacid</strong></p><p>(raltegravir 1,200 mg single dose)</p></td><td style="vertical-align:top"><p><u>12 hours after raltegravir</u> raltegravir AUC &macr; 14% raltegravir C24 hr &macr;&nbsp;58%&nbsp;raltegravir Cmax &macr;&nbsp;14%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(chelation of metal ions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>calcium carbonate antacid</strong></p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 55%</p></td><td style="vertical-align:top"><p>No dose adjustment required</p></td></tr><tr><td style="vertical-align:top"><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir&nbsp;C12 hr &macr;&nbsp;32%</p></td><td style="vertical-align:top"><p>for raltegravir (400 mg twice</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>raltegravir&nbsp;Cmax &macr;&nbsp;52%</p></td><td style="vertical-align:top"><p>daily).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(chelation of metal cations)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal</strong><strong> </strong><strong>products by therapeutic </strong><strong>area</strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p>(mechanism, if known)</p></td><td style="vertical-align:top"><p><strong>Recommendations</strong><strong> </strong><strong>concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>calcium</strong><strong> </strong><strong>carbonate</strong><strong> </strong><strong>antacid</strong></p><p>(raltegravir 1,200 mg single dose)</p></td><td style="vertical-align:top"><p>raltegravir AUC &macr; 72% raltegravir C24 hr &macr;&nbsp;48% raltegravir Cmax &macr;&nbsp;74%</p><p><strong>&nbsp;</strong></p><p><u>12 hours after raltegravir</u> raltegravir AUC &macr; 10% raltegravir C24 hr &macr;&nbsp;57%&nbsp;raltegravir Cmax &macr;&nbsp;2%</p><p><strong>&nbsp;</strong></p><p>(chelation of metal ions)</p></td><td style="vertical-align:top"><p>Co-administration of raltegravir (1,200 mg once daily) is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Other METAL CATION</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Iron</strong><strong> </strong><strong>salts</strong></p></td><td style="vertical-align:top"><p>Expected:</p><p>Raltegravir AUC &macr; (chelation of metal cations)</p></td><td style="vertical-align:top"><p>Given simultaneously iron salts are expected to reduce raltegravir plasma levels; taking iron salts at least two hours from the administration of raltegravir may allow to</p><p>limit this effect.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>H2</strong><strong> </strong><strong>BLOCKERS</strong><strong> </strong><strong>AND PROTON PUMP INHIBITORS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>omeprazole</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &uarr; 37% raltegravir C12 hr &uarr; 24% raltegravir Cmax &uarr; 51%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(increased solubility)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>famotidine</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>raltegravir AUC &uarr; 44% raltegravir C12 hr &uarr; 6% raltegravir Cmax &uarr; 60%</p><p><strong>&nbsp;</strong></p><p>(increased solubility)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>No dose adjustment required</p><p>for raltegravir (400 mg twice daily and 1,200 mg once daily).</p></td></tr><tr><td style="vertical-align:top"><p><strong>gastric pH altering agents: </strong>proton pump inhibitors (e.g. omeprazole), H2 blockers (e.g. famotidine, ranitidine, cimitedine)</p><p><strong>&nbsp;</strong></p><p>(raltegravir 1,200 mg)</p></td><td style="vertical-align:top"><p>Population PK analysis showed that the effect of gastric pH altering agents on raltegravir pharmacokinetics was minimal (8.8% decrease in relative bioavailability), and was not statistically or clinically significant.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Increased drug solubility)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HORMONAL</strong><strong> </strong><strong>CONTRACEPTIVES</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ethinyl Estradiol</strong><strong> </strong><strong>Norelgestromin</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>Ethinyl Estradiol AUC &macr; 2% Ethinyl Estradiol Cmax &uarr; 6% Norelgestromin AUC &uarr; 14% Norelgestromin Cmax &uarr; 29%</p></td><td style="vertical-align:top"><p>No dosage adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily) or hormonal contraceptives (estrogen- and/or</p><p>progesterone-based).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OPIOID</strong><strong> </strong><strong>ANALGESICS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>methadone</strong></p><p>(raltegravir 400 mg Twice Daily)</p></td><td style="vertical-align:top"><p>methadone AUC &harr;</p><p>methadone Cmax &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily)</p><p>or methadone.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no data for the use of raltegravir 1,200&nbsp;mg once daily in pregnant women. A large amount of data on pregnant women with exposure to raltegravir 400&nbsp;mg twice daily during the first trimester (more than 1,000&nbsp;prospective pregnancy outcomes) indicates no malformative toxicity. Animal studies have shown reproductive toxicity (see section&nbsp;5.3).</p><p>A moderate amount of data on pregnant women with exposure to raltegravir 400&nbsp;mg twice daily during the second and/or third trimester (between 300-1,000 prospective pregnancy outcomes) indicates no increased risk of feto/neonatal toxicity.</p><p>&nbsp;</p><p>Raltegravir 1,200&nbsp;mg is not recommended during pregnancy.</p><p><s>&nbsp;</s></p><p><em>Anti-retroviral Pregnancy Registry</em></p><p>To monitor maternal-foetal outcomes in patients inadvertently administered raltegravir while pregnant, an Anti-retroviral Pregnancy Registry has been established. Physicians are encouraged to register patients in this registry.</p><p>&nbsp;</p><p>As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account in order to characterise the safety for the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>Raltegravir/metabolites are excreted in human milk to such an extent that effects on the breastfed newborns/infants are likely. Available pharmacodynamics/toxicological data in animals have shown excretion of raltegravir/metabolites in milk (for details see section&nbsp;5.3).</p><p>&nbsp;</p><p>A risk to the newborns/infants cannot be excluded.</p><p>&nbsp;</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>No effect on fertility was seen in male and female rats at doses up to 600&nbsp;mg/kg/day which resulted in 3‑fold exposure above the exposure at the recommended human dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:14.25pt">Dizziness has been reported in some patients during treatment with regimens containing raltegravir. Dizziness may influence some patients&#39; ability to drive and use machines (see section 4.8).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Summary of the safety profile</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:7.9pt">The safety profile of raltegravir was established in two Phase III randomised clinical studies in treatment-experienced adult patients and two Phase III randomised clinical studies in treatment-na&iuml;ve adult patients. Data from post-authorisation safety studies and spontaneous reporting have also contributed to the safety profile of raltegravir.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:9.05pt">In treatment-experienced patients, the two clinical studies used the recommended dose of 400 mg twice daily in combination with optimised background therapy (OBT) in 462 patients, in comparison to 237 patients taking placebo in combination with OBT. During double-blind treatment, the total follow-up was 708 patient-years in the group receiving raltegravir 400 mg twice daily, and</p><p style="margin-left:5.9pt; margin-right:-1.0pt">244 patient-years in the group receiving placebo.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:23.45pt">In treatment-na&iuml;ve patients, one study used the recommended dose of 400 mg twice daily in combination with a fixed dose of emtricitabine 200 mg (+) tenofovir disoproxil fumarate 245 mg in</p><p style="margin-left:10.9pt; margin-right:-1.0pt">281 patients, in comparison to 282 patients taking efavirenz (EFV) 600 mg (at bedtime) in</p><p style="margin-left:10.9pt; margin-right:15.75pt">combination with emtricitabine (+) tenofovir disoproxil fumarate. During double-blind treatment, the total follow-up was 1,104 patient-years in the group receiving raltegravir 400 mg twice daily, and</p><p style="margin-left:10.9pt; margin-right:21.65pt">1,036 patient-years in the group receiving efavirenz 600 mg at bedtime. The second study evaluated raltegravir in 797 treatment-na&iuml;ve HIV-1 infected patients, comparing 531 patients receiving raltegravir 1,200 mg once daily with 266 patients receiving raltegravir 400 mg twice daily, each in</p><p style="margin-left:10.9pt; margin-right:17.2pt">combination with emtricitabine (+) tenofovir disoproxil fumarate. The total follow-up for patients on raltegravir 1,200 mg once daily was 515.6 patient-years and for raltegravir 400 mg twice daily was</p><p style="margin-left:10.9pt; margin-right:-1.0pt">257.7 patient-years.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:25.3pt">The most frequently reported adverse reactions during treatment were headache and nausea and abdominal pain, occurring at 5% or greater. The most frequently reported serious adverse reactions were immune reconstitution syndrome and serious rash. Rhabdomyolysis was an uncommonly reported serious adverse reaction in post-marketing use of raltegravir 400 mg twice daily.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:9.35pt">In the pooled analysis of treatment-experienced patients, the rates of discontinuation of therapy due to adverse reactions were 3.9 % in patients receiving raltegravir + OBT and 4.6 % in patients receiving placebo + OBT. The rates of discontinuation of therapy in na&iuml;ve patients due to adverse reactions were</p><p style="margin-left:10.9pt; margin-right:13.15pt">5.0 % in patients receiving raltegravir + emtricitabine (+) tenofovir disoproxil fumarate and 10.0 % in patients receiving efavirenz + emtricitabine (+) tenofovir disoproxil fumarate.</p><p style="margin-left:0in; margin-right:0in"><u>&nbsp;</u></p><p style="margin-left:10.9pt; margin-right:-1.0pt"><u>Tabulated summary of adverse reactions</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:17.7pt">Adverse reactions considered by investigators to be causally related to raltegravir (alone or in combination with other ART), as well as adverse reactions established in post-marketing experience, are listed below by System Organ Class. Frequencies are defined as common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), and not known (cannot be estimated from the available data).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:1.95in"><p style="margin-left:22.5pt; margin-right:-1.0pt"><strong>System Organ Class</strong></p></td><td style="border-color:black; height:38.4pt; vertical-align:top; width:99.0pt"><p style="margin-left:24.05pt; margin-right:-1.0pt"><strong>Frequency</strong></p></td><td style="border-color:black; height:38.4pt; vertical-align:top; width:225.0pt"><p style="margin-left:68.3pt; margin-right:67.35pt; text-align:center"><strong>Adverse reactions</strong></p><p style="margin-left:13.3pt; margin-right:12.25pt; text-align:center"><strong>Raltegravir (alone or in combination with other ART)</strong></p></td></tr><tr><td style="border-color:black; height:63.7pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Infections and infestations</p></td><td style="height:63.7pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:63.7pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">genital herpes, folliculitis, gastroenteritis, herpes</p><p style="margin-left:5.1pt; margin-right:4.1pt">simplex, herpes virus infection, herpes zoster, influenza, lymph node abscess, molluscum contagiosum, nasopharyngitis, upper respiratory tract infection</p></td></tr><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Neoplasms benign,</p><p style="margin-left:5.1pt; margin-right:-1.0pt">malignant and unspecified</p><p style="margin-left:5.1pt; margin-right:-1.0pt">(including cysts and polyps)</p></td><td style="height:38.5pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:38.5pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">skin papilloma</p></td></tr><tr><td style="border-color:black; height:51.1pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Blood and lymphatic system</p><p style="margin-left:5.1pt; margin-right:-1.0pt">disorders</p></td><td style="height:51.1pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:51.1pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">anaemia, iron deficiency anaemia, lymph node</p><p style="margin-left:5.1pt; margin-right:52.8pt">pain, lymphadenopathy, neutropenia, thrombocytopenia</p></td></tr><tr><td style="border-color:black; height:25.7pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Immune system disorders</p></td><td style="height:25.7pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:25.7pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">immune reconstitution syndrome, drug</p><p style="margin-left:5.1pt; margin-right:-1.0pt">hypersensitivity, hypersensitivity</p></td></tr><tr><td style="border-color:black; height:79.9pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Metabolism and nutrition</p><p style="margin-left:5.1pt; margin-right:-1.0pt">disorders</p></td><td style="height:79.9pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:79.9pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">decreased appetite</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.1pt; margin-right:28.1pt">cachexia, diabetes mellitus, dyslipidaemia, hypercholesterolaemia, hyperglycaemia, hyperlipidaemia, hyperphagia, increased appetite, polydipsia, body fat disorder</p></td></tr><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Psychiatric disorders</p></td><td style="height:38.5pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p></td><td style="height:38.5pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">abnormal dreams, insomnia, nightmare,</p><p style="margin-left:5.1pt; margin-right:-1.0pt">abnormal behaviour, depression</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:1.95in"><p style="margin-left:22.5pt; margin-right:-1.0pt"><strong>System Organ Class</strong></p></td><td style="border-color:black; height:38.5pt; vertical-align:top; width:99.0pt"><p style="margin-left:24.05pt; margin-right:-1.0pt"><strong>Frequency</strong></p></td><td style="border-color:black; height:38.5pt; vertical-align:top; width:225.0pt"><p style="margin-left:68.3pt; margin-right:67.35pt; text-align:center"><strong>Adverse reactions</strong></p><p style="margin-left:13.3pt; margin-right:12.25pt; text-align:center"><strong>Raltegravir (alone or in combination with other ART)</strong></p></td></tr><tr><td style="border-color:black; height:89.05pt; vertical-align:top; width:1.95in"><p>&nbsp;</p></td><td style="height:89.05pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:89.05pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">mental disorder, suicide attempt, anxiety,</p><p style="margin-left:5.1pt; margin-right:24.1pt">confusional state, depressed mood, major depression, middle insomnia, mood altered,</p><p style="margin-left:5.1pt; margin-right:-1.0pt">panic attack, sleep disorder, suicidal ideation,</p><p style="margin-left:5.1pt; margin-right:7.55pt">suicidal behaviour (particularly in patients with a pre-existing history of psychiatric illness)</p></td></tr><tr><td style="border-color:black; height:114.35pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Nervous system disorders</p></td><td style="height:114.35pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:114.35pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">dizziness, headache, psychomotor hyperactivity</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:12.85pt">amnesia, carpal tunnel syndrome, cognitive disorder, disturbance in attention, dizziness postural, dysgeusia, hypersomnia, hypoaesthesia, lethargy, memory impairment, migraine, neuropathy peripheral, paraesthesia, somnolence, tension headache, tremor, poor quality sleep</p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Eye disorders</p></td><td style="height:13.1pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:13.1pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">visual impairment</p></td></tr><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Ear and labyrinth disorders</p></td><td style="height:38.5pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:38.5pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">vertigo</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">tinnitus</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Cardiac disorders</p></td><td style="height:25.8pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">palpitations, sinus bradycardia, ventricular</p><p style="margin-left:5.1pt; margin-right:-1.0pt">extrasystoles</p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Vascular disorders</p></td><td style="height:13.1pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:13.1pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">hot flush, hypertension</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Respiratory, thoracic and</p><p style="margin-left:5.1pt; margin-right:-1.0pt">mediastinal disorders</p></td><td style="height:25.8pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">dysphonia, epistaxis, nasal congestion</p></td></tr><tr><td style="border-color:black; height:139.7pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Gastrointestinal disorders</p></td><td style="height:139.7pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:139.7pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">abdominal distention, abdominal pain,</p><p style="margin-left:5.1pt; margin-right:42.5pt">diarrhoea, flatulence, nausea, vomiting, dyspepsia</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:3.4pt">gastritis, abdominal discomfort, abdominal pain upper, abdominal tenderness, anorectal discomfort, constipation, dry mouth, epigastric discomfort, erosive duodenitis, eructation, gastrooesophageal reflux disease, gingivitis, glossitis, odynophagia, pancreatitis acute, peptic ulcer, rectal haemorrhage</p></td></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Hepato-biliary disorders</p></td><td style="height:38.4pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:38.4pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">hepatitis, hepatic steatosis, hepatitis alcoholic,</p><p style="margin-left:5.1pt; margin-right:-1.0pt">hepatic failure</p></td></tr><tr><td style="border-color:black; height:152.9pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Skin and subcutaneous tissue</p><p style="margin-left:5.1pt; margin-right:-1.0pt">disorders</p></td><td style="height:152.9pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:152.9pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">rash</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:4.65pt">acne, alopecia, dermatitis acneiforme, dry skin, erythema, facial wasting, hyperhidrosis, lipoatrophy, lipodystrophy acquired, lipohypertrophy, night sweats, prurigo, pruritus, pruritus generalised, rash macular, rash maculo- papular, rash pruritic, skin lesion, urticaria, xeroderma, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:1.95in"><p style="margin-left:22.5pt; margin-right:-1.0pt"><strong>System Organ Class</strong></p></td><td style="border-color:black; height:38.5pt; vertical-align:top; width:99.0pt"><p style="margin-left:24.05pt; margin-right:-1.0pt"><strong>Frequency</strong></p></td><td style="border-color:black; height:38.5pt; vertical-align:top; width:225.0pt"><p style="margin-left:68.3pt; margin-right:67.35pt; text-align:center"><strong>Adverse reactions</strong></p><p style="margin-left:13.3pt; margin-right:12.25pt; text-align:center"><strong>Raltegravir (alone or in combination with other ART)</strong></p></td></tr><tr><td style="border-color:black; height:51.1pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Musculoskeletal and</p><p style="margin-left:5.1pt; margin-right:-1.0pt">connective tissue disorders</p></td><td style="height:51.1pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:51.1pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">arthralgia, arthritis, back pain, flank pain,</p><p style="margin-left:5.1pt; margin-right:32.05pt">musculoskeletal pain, myalgia, neck pain, osteopenia, pain in extremity, tendonitis,</p><p style="margin-left:5.1pt; margin-right:-1.0pt">rhabdomyolysis</p></td></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Renal and urinary disorders</p></td><td style="height:38.4pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:38.4pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">renal failure, nephritis, nephrolithiasis, nocturia,</p><p style="margin-left:5.1pt; margin-right:14.65pt">renal cyst, renal impairment, tubulointerstitial nephritis</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Reproductive system and</p><p style="margin-left:5.1pt; margin-right:-1.0pt">breast disorders</p></td><td style="height:25.8pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">erectile dysfunction, gynaecomastia,</p><p style="margin-left:5.1pt; margin-right:-1.0pt">menopausal symptoms</p></td></tr><tr><td style="border-color:black; height:63.7pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">General disorders and</p><p style="margin-left:5.1pt; margin-right:50.05pt">administration site conditions</p></td><td style="height:63.7pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:63.7pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">asthenia, fatigue, pyrexia</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:8.2pt">chest discomfort, chills, face oedema, fat tissue increased, feeling jittery, malaise, submandibular mass, oedema peripheral, pain</p></td></tr><tr><td style="border-color:black; height:240.85pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Investigations</p></td><td style="height:240.85pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:240.85pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">alanine aminotransferase increased, atypical</p><p style="margin-left:5.1pt; margin-right:10.95pt">lymphocytes, aspartate aminotransferase increased, blood triglycerides increased, lipase increased, blood pancreatic amylase increased</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:5.55pt">absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:1.95in"><p style="margin-left:5.1pt; margin-right:-1.0pt">Injury, poisoning and</p><p style="margin-left:5.1pt; margin-right:-1.0pt">procedural complications</p></td><td style="height:25.8pt; vertical-align:top; width:99.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:225.0pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">accidental overdose</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:-1.0pt"><u>Description of selected adverse reactions</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:19.05pt">In studies of raltegravir 400 mg twice daily, cancers were reported in treatment-experienced and treatment-na&iuml;ve patients who initiated raltegravir in conjunction with other antiretroviral agents. The types and rates of specific cancers were those expected in a highly immunodeficient population. The risk of developing cancer in these studies was similar in the groups receiving raltegravir and in the groups receiving comparators.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:15.65pt">Grade 2-4 creatine kinase laboratory abnormalities were observed in subjects treated with raltegravir. Myopathy and rhabdomyolysis have been reported. Use with caution in patients who have had myopathy or rhabdomyolysis in the past or have any predisposing issues including other medicinal products associated with these conditions (see section 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.9pt; margin-right:19.3pt; text-align:justify">Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). The frequency of this is unknown (see section 4.4).</p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:19.95pt">In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.15pt">For each of the following clinical adverse reactions there was at least one serious occurrence: genital herpes, anaemia, immune reconstitution syndrome, depression, mental disorder, suicide attempt, gastritis, hepatitis, renal failure, accidental overdose.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:6.0pt">In clinical studies of treatment-experienced patients, rash, irrespective of causality, was more commonly observed with regimens containing raltegravir and darunavir compared to those containing raltegravir without darunavir or darunavir without raltegravir. Rash considered by the investigator to be drug-related occurred at similar rates. The exposure-adjusted rates of rash (all causality) were 10.9,</p><p style="margin-left:5.9pt; margin-right:5.4pt">4.2, and 3.8 per 100 patient-years (PYR), respectively; and for drug-related rash were 2.4, 1.1, and 2.3 per 100 PYR, respectively. The rashes observed in clinical studies were mild to moderate in severity</p><p style="margin-left:5.9pt; margin-right:-1.0pt">and did not result in discontinuation of therapy (see section 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Patients co-infected with hepatitis B and/or hepatitis C virus</em></p><p style="margin-left:5.9pt; margin-right:25.05pt">In Phase III studies of raltegravir, patients with chronic (but not acute) active hepatitis B and/or hepatitis C co-infection were permitted to enroll provided that baseline liver function tests did not</p><p style="margin-left:5.9pt; margin-right:-1.0pt">exceed 5 times the upper limit of normal. In the treatment experienced studies, BENCHMRK 1 and</p><p style="margin-left:5.9pt; margin-right:15.15pt">BENCHMRK 2 (Protocol 018 and Protocol 019), 16% of all patients (114/699) were co-infected; in the treatment-na&iuml;ve studies, STARTMRK (Protocol 021) and ONCEMRK (Protocol 292), 6%</p><p style="margin-left:5.9pt; margin-right:-1.0pt">(34/563) and 2.9% (23/797), respectively, were co-infected. In general the safety profile of raltegravir</p><p style="margin-left:5.9pt; margin-right:7.45pt">in patients with hepatitis B and/or hepatitis C virus co-infection was similar to that in patients without hepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT abnormalities were somewhat higher in the subgroup with hepatitis B and/or hepatitis C virus co-infection for both treatment groups.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:3.65pt">At 96-weeks, in treatment-experienced patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 29 %, 34 % and</p><p style="margin-left:5.9pt; margin-right:3.1pt">13 %, respectively, of co-infected subjects treated with raltegravir as compared to 11 %, 10 % and 9 % of all other subjects treated with raltegravir. At 240-weeks, in treatment-na&iuml;ve patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total</p><p style="margin-left:5.9pt; margin-right:47.9pt">bilirubin occurred in 22 %, 44 % and 17 %, respectively, of co-infected subjects treated with raltegravir as compared to 13 %, 13 % and 5 % of all other subjects treated with raltegravir.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Paediatric population</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">Isentress 600 mg tablet formulation has not been studied in paediatric patients (see section 4.2).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:5.1pt">&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Reporting of suspected adverse reactions</u></p><p style="margin-left:5.9pt; margin-right:23.3pt">Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions :</p><p style="margin-left:5.9pt; margin-right:23.3pt">&nbsp;</p><p style="margin-left:0in; margin-right:27.6pt"><strong>&nbsp; To report any side effect(s):</strong></p><p style="margin-left:4.5pt; text-indent:9.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p style="text-align:justify; text-indent:9.0pt">The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p style="text-align:justify; text-indent:9.0pt">o Fax: +966-11-205-7662</p><p style="text-align:justify; text-indent:9.0pt">o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:justify; text-indent:9.0pt">o Toll free phone: 8002490000</p><p style="text-align:justify; text-indent:9.0pt">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:justify; text-indent:9.0pt">o Website: www.sfda.gov.sa/npc</p><p style="margin-left:4.5pt; text-indent:9.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p style="text-align:justify; text-indent:9.0pt">Please contact the relevant competent authority.</p><p style="margin-left:5.9pt; margin-right:23.3pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt">No specific information is available on the treatment of overdose with raltegravir.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:2.7pt">In the event of an overdose, it is reasonable to employ the standard supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required. It should be taken into account that raltegravir is presented for clinical use as the potassium salt. The extent to which raltegravir may be dialysable is unknown.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:39.45pt">Pharmacotherapeutic group: antivirals for systemic use, other antivirals, ATC code: J05AX08. <u>Mechanism of action</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:6.3pt">Raltegravir is an integrase strand transfer inhibitor active against the Human Immunodeficiency Virus (HIV-1). Raltegravir inhibits the catalytic activity of integrase, an HIV-encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of the HIV genome into the host cell genome. HIV genomes that fail to integrate cannot direct the production of new infectious viral particles, so inhibiting integration prevents propagation of the viral infection.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Antiviral activity in vitro</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:20.8pt; text-align:justify">Raltegravir at concentrations of 31 &plusmn; 20 nM resulted in 95 % inhibition (IC95) of HIV-1 replication</p><p style="margin-left:5.9pt; margin-right:17.75pt; text-align:justify">(relative to an untreated virus-infected culture) in human T-lymphoid cell cultures infected with the</p><p style="margin-left:5.9pt; margin-right:2.85pt">cell-line adapted HIV-1 variant H9IIIB. In addition, raltegravir inhibited viral replication in cultures of mitogen-activated human peripheral blood mononuclear cells infected with diverse, primary clinical</p><p style="margin-left:5.9pt; margin-right:50.05pt; text-align:justify">isolates of HIV-1, including isolates from 5 non-B subtypes, and isolates resistant to reverse</p><p style="margin-left:5.9pt; margin-right:10.55pt; text-align:justify">transcriptase inhibitors and protease inhibitors. In a single-cycle infection assay, raltegravir inhibited infection of 23 HIV isolates representing 5 non-B subtypes and 5 circulating recombinant forms with IC50 values ranging from 5 to 12 nM.</p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Resistance</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:6.4pt">Resistance analyses were performed in twice daily and once daily studies of raltegravir. In twice daily studies, most viruses isolated from patients failing raltegravir had high-level raltegravir resistance resulting from the appearance of two or more mutations. Most had a signature mutation at amino acid</p><p style="margin-left:5.9pt; margin-right:12.35pt">155 (N155 changed to H), amino acid 148 (Q148 changed to H, K, or R), or amino acid 143 (Y143 changed to H, C, or R), along with one or more additional integrase mutations (e.g., L74M, E92Q, T97A, E138A/K, G140A/S, V151I, G163R, S230R). The signature mutations decrease viral susceptibility to raltegravir and addition of other mutations results in a further decrease in raltegravir susceptibility. Raltegravir mutations identified in a once daily study were similar to those previously identified in twice daily studies (N155H, N155H/I203M and L74M/E92Q)<em>. </em>Factors that reduced the likelihood of developing resistance included lower baseline viral load and use of other active</p><p style="margin-left:5.9pt; margin-right:6.2pt">anti-retroviral agents. Mutations conferring resistance to raltegravir generally also confer resistance to the integrase strand transfer inhibitor elvitegravir. Mutations at amino acid 143 confer greater</p><p style="margin-left:5.9pt; margin-right:-1.0pt">resistance to raltegravir than to elvitegravir, and the E92Q mutation confers greater resistance to</p><p style="margin-left:5.9pt; margin-right:19.45pt">elvitegravir than to raltegravir. Viruses harbouring a mutation at amino acid 148, along with one or more other raltegravir resistance mutations, may also have clinically significant resistance to dolutegravir.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Clinical experience</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:30.15pt">The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients, the analysis of 240-week data from randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-na&iuml;ve HIV-1 infected adult patients and the analysis of</p><p style="margin-left:5.9pt; margin-right:33.75pt">48-week data from randomised, double-blind, active-control trial (ONCEMRK Protocol 292) in antiretroviral treatment-na&iuml;ve HIV-1 infected adult patients.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Efficacy</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Treatment-experienced adult patients (400 mg twice daily)</em></p><p style="margin-left:5.9pt; margin-right:-1.0pt">BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled</p><p style="margin-left:5.9pt; margin-right:2.3pt">trials) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimized background therapy (OBT), in HIV-infected patients, 16 years or older,</p><p style="margin-left:5.9pt; margin-right:-1.0pt">with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of</p><p style="margin-left:5.9pt; margin-right:10.05pt">anti-retroviral therapies. Prior to randomization, OBT were selected by the investigator based on the patient&#39;s prior treatment history, as well as baseline genotypic and phenotypic viral resistance testing.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:3.05pt">Patient demographics (gender, age and race) and baseline characteristics were comparable between the groups receiving raltegravir 400 mg twice daily and placebo. Patients had prior exposure to a median</p><p style="margin-left:5.9pt; margin-right:-1.0pt">of 12 anti-retrovirals for a median of 10 years. A median of 4 ARTs was used in OBT.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Results 48-week and 96-week analyses</em></p><p style="margin-left:5.9pt; margin-right:9.9pt">Durable outcomes (Week 48 and Week 96) for patients on the recommended dose raltegravir 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 2.</p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:-1.0pt"><strong>Table 2</strong></p><p style="margin-left:11.9pt; margin-right:-1.0pt"><strong>Efficacy Outcome at Weeks 48 and 96</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:-3.5pt"><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:65.5pt;margin-top:1.05pt;width:515.75pt;
 height:.1pt;z-index:-2149;mso-position-horizontal-relative:page'
 coordorigin="1310,21" coordsize="10315,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1310;top:21;width:10315;
  height:2' coordorigin="1310,21" coordsize="10315,0" path="m1310,21r10316,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="691" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1028" style='position:absolute;left:0;text-align:left;
 margin-left:273.5pt;margin-top:14.6pt;width:307.8pt;height:.1pt;z-index:-2148;
 mso-position-horizontal-relative:page' coordorigin="5470,292" coordsize="6156,2">
 <v:shape id="_x0000_s1029" style='position:absolute;left:5470;top:292;width:6156;
  height:2' coordorigin="5470,292" coordsize="6156,0" path="m5470,292r6156,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="412" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[endif]--><strong>BENCHMR</strong><strong>K 1 and 2 Pooled</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><strong>4</strong><strong>8 Weeks&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 96 Weeks</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.9pt; margin-right:-1.0pt"><strong>Para</strong><strong>m</strong><strong>eter</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:-3.5pt"><!--[if gte vml 1]><v:group id="_x0000_s1030" style='position:absolute;
 left:0;text-align:left;margin-left:65.5pt;margin-top:-.15pt;width:515.75pt;
 height:.1pt;z-index:-2147;mso-position-horizontal-relative:page'
 coordorigin="1310,-3" coordsize="10315,2">
 <v:shape id="_x0000_s1031" style='position:absolute;left:1310;top:-3;width:10315;
  height:2' coordorigin="1310,-3" coordsize="10315,0" path="m1310,-3r10316,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="689" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[endif]--><strong>Percent HIV-RNA &lt; 400 copies/ml (95 % CI)</strong></p><p>&nbsp;</p><p style="margin-left:1.25pt; margin-right:.25pt; text-align:center"><strong>Raltegravir</strong></p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>40</strong><strong>0 mg twice daily + OBT (N = 462)</strong></p><p>&nbsp;</p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>Placebo + OBT</strong></p><p style="margin-left:-.8pt; margin-right:-1.95pt; text-align:center"><strong>(</strong><strong>N = 237)</strong></p><p>&nbsp;</p><p style="margin-left:1.25pt; margin-right:.25pt; text-align:center"><strong>Raltegravir</strong></p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>40</strong><strong>0 mg twice daily + OBT (N = 462)</strong></p><p>&nbsp;</p><p style="margin-left:-.85pt; margin-right:24.85pt; text-align:center"><strong>Placebo + OBT</strong></p><p style="margin-left:-.8pt; margin-right:24.85pt; text-align:center"><strong>(</strong><strong>N = 237)</strong></p><p>&nbsp;</p><p style="margin-left:39.5pt; margin-right:22.45pt; text-indent:-9.95pt">All patients&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 72 (68, 76)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37 (31, 44)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 62 (57, 66)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28 (23, 34) Baseline Characteristic&Dagger;</p><p style="margin-left:49.6pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 62 (53, 69)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17 (9, 27)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53 (45, 61)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15 (8, 25)</p><p style="margin-left:49.6pt; margin-right:22.4pt; text-indent:47.4pt">&le; 100,000 copies/ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 82 (77, 86)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49 (41, 58)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 74 (69, 79)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39 (31, 47) CD4-count &le; 50 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61 (53, 69)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21 (13, 32)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 51 (42, 60)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14 (7, 24)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">&gt; 50 and &le; 200 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80 (73, 85)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44 (33, 55)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 70 (62, 77)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36 (25, 48)</p><p style="margin-left:52.0pt; margin-right:22.4pt; text-indent:45.0pt">&gt; 200 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 83 (76, 89)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 51 (39, 63)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 78 (70, 85)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42 (30, 55) Sensitivity score (GSS) &sect;</p><p style="margin-left:97.0pt; margin-right:-1.0pt">0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52 (42, 61)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 (3, 17)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46 (36, 56)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 (1, 13)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 81 (75, 87)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 (30, 51)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 76 (69, 83)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31 (22, 42)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">2 and above&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 84 (77, 89)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65 (52, 76)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71 (63, 78)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56 (43, 69)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.9pt; margin-right:-1.0pt"><!--[if gte vml 1]><v:group id="_x0000_s1032" style='position:absolute;
 left:0;text-align:left;margin-left:65.5pt;margin-top:-.15pt;width:515.75pt;
 height:.1pt;z-index:-2146;mso-position-horizontal-relative:page'
 coordorigin="1310,-3" coordsize="10315,2">
 <v:shape id="_x0000_s1033" style='position:absolute;left:1310;top:-3;width:10315;
  height:2' coordorigin="1310,-3" coordsize="10315,0" path="m1310,-3r10316,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="689" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[endif]--><strong>Percent HIV-RNA &lt; 50 copies/ml (95 % CI)</strong></p><p style="margin-left:27.7pt; margin-right:22.45pt; text-align:center">All patients&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 62 (57, 67)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33 (27, 39)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 57 (52, 62)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26 (21, 32)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:37.65pt; margin-right:390.25pt; text-align:center">Baseline Characteristic&Dagger;</p><p style="margin-left:49.6pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48 (40, 56)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16 (8, 26)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47 (39, 55)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13 (7, 23)</p><p style="margin-left:49.6pt; margin-right:22.4pt; text-indent:47.4pt">&le; 100,000 copies/ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73 (68, 78)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43 (35, 52)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 70 (64, 75)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36 (28, 45) CD4-count &le; 50 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50 (41, 58)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 (12, 31)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50 (41, 58)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13 (6, 22)</p><p style="margin-left:94.6pt; margin-right:-1.0pt">&gt; 50 and &le; 200 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 67 (59, 74)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39 (28, 50)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65 (57, 72)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32 (22, 44)</p><p style="margin-left:52.0pt; margin-right:22.4pt; text-indent:45.0pt">&gt; 200 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 76 (68, 83)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44 (32, 56)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71 (62, 78)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41 (29, 53) Sensitivity score (GSS) &sect;</p><p style="margin-left:97.0pt; margin-right:-1.0pt">0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45 (35, 54)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 (0, 11)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41 (32, 51)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 (1, 13)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 67 (59, 74)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37 (27, 48)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 72 (64, 79)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28 (19, 39)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">2 and above&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 75 (68, 82)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 59 (46, 71)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65 (56, 72)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53 (40, 66)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.9pt; margin-right:-1.0pt"><!--[if gte vml 1]><v:group id="_x0000_s1034" style='position:absolute;
 left:0;text-align:left;margin-left:65.5pt;margin-top:1.1pt;width:515.75pt;
 height:.1pt;z-index:-2145;mso-position-horizontal-relative:page'
 coordorigin="1310,22" coordsize="10315,2">
 <v:shape id="_x0000_s1035" style='position:absolute;left:1310;top:22;width:10315;
  height:2' coordorigin="1310,22" coordsize="10315,0" path="m1310,22r10316,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="689" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[endif]--><strong>M</strong><strong>e</strong><strong>an CD4 Cell Change (95 % CI), cells/mm</strong><strong>3</strong></p><p style="margin-left:39.5pt; margin-right:22.4pt; text-indent:-9.95pt">All patients&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 109 (98, 121)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45 (32, 57)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 123 (110, 137)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49 (35, 63) Baseline Characteristic&Dagger;</p><p style="margin-left:49.6pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 126 (107, 144)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36 (17, 55)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 140 (115, 165)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 (16, 65)</p><p style="margin-left:49.6pt; margin-right:22.4pt; text-indent:47.4pt">&le; 100,000 copies/ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100 (86, 115)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49 (33, 65)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 114 (98, 131)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53 (36, 70) CD4-count &le; 50 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 121 (100, 142)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33 (18, 48)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 130 (104, 156)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42 (17, 67)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">&gt; 50 and &le; 200 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 104 (88, 119)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47 (28, 66)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 123 (103, 144)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56 (34, 79)</p><p style="margin-left:52.0pt; margin-right:22.4pt; text-indent:45.0pt">&gt; 200 cells/mm3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 104 (80, 129)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54 (24, 84)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 117 (90, 143)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48 (23, 73) Sensitivity score (GSS) &sect;</p><p style="margin-left:97.0pt; margin-right:-1.0pt">0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 81 (55, 106)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11 (4, 26)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 97 (70, 124)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15 (-0, 31)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 113 (96, 130)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44 (24, 63)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 132 (111, 154)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45 (24, 66)</p><p style="margin-left:97.0pt; margin-right:-1.0pt">2 and above&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 125 (105, 144)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 76 (48, 103)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 134 (108, 159)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90 (57, 123)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:19.95pt; margin-right:36.65pt; text-indent:-8.05pt"><!--[if gte vml 1]><v:group id="_x0000_s1036" style='position:absolute;
 left:0;text-align:left;margin-left:65.5pt;margin-top:1.35pt;width:515.75pt;
 height:.1pt;z-index:-2144;mso-position-horizontal-relative:page'
 coordorigin="1310,27" coordsize="10315,2">
 <v:shape id="_x0000_s1037" style='position:absolute;left:1310;top:27;width:10315;
  height:2' coordorigin="1310,27" coordsize="10315,0" path="m1310,27r10316,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="689" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[endif]-->&dagger; Non-completer is failure imputation: patients who discontinued prematurely are imputed as failure thereafter. Percent of patients with response and associated 95 % confidence interval (CI) are reported.</p><p style="margin-left:11.9pt; margin-right:-1.0pt">&Dagger; For analysis by prognostic factors, virologic failures were carried forward for percent &lt; 400 and 50 copies/ml. For mean CD4 changes, baseline-carry-</p><p style="margin-left:19.95pt; margin-right:-1.0pt">forward was used for virologic failures.</p><p style="margin-left:11.9pt; margin-right:-1.0pt">&sect; The Genotypic Sensitivity Score (GSS) was defined as the total oral ARTs in the optimised background therapy (OBT) to which a patient&#39;sviral isolate</p><p style="margin-left:18.35pt; margin-right:12.85pt; text-align:center">showed genotypic sensitivity based upon genotypic resistance test. Enfuvirtide use in OBT in enfuvirtide-na&iuml;ve patients was counted as one active drug in</p><p style="margin-left:4.2pt; margin-right:3.4pt; text-align:center"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OBT. Similarly, darunavir use in OBT in darunavir-na&iuml;ve patients was counted as one active drug in OBT. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.9pt; margin-right:-1.0pt">Raltegravir achieved virologic responses (using Not Completer=Failure approach) of HIV RNA</p><p style="margin-left:11.9pt; margin-right:80.75pt">&lt; 50 copies/ml in 61.7 % of patients at Week 16, in 62.1 % at Week 48 and in 57.0 % at Week 96. Some patients experienced viral rebound between Week 16 and Week 96. Factors associated with</p><p style="margin-left:11.9pt; margin-right:-1.0pt">failure include high baseline viral load and OBT that did not include at least one potent active agent.</p><p>&nbsp;</p><p style="margin-left:8.9pt; margin-right:-1.0pt"><em>Switch to raltegravir (400 mg twice daily)</em></p><p style="margin-left:8.9pt; margin-right:62.15pt">The SWITCHMRK 1 &amp; 2 (Protocols 032 &amp; 033) studies evaluated HIV-infected patients receiving suppressive (screening HIV RNA &lt; 50 copies/ml; stable regimen &gt; 3 months) therapy with lopinavir</p><p style="margin-left:8.9pt; margin-right:52.55pt">200 mg (+) ritonavir 50 mg 2 tablets twice daily plus at least 2 nucleoside reverse transcriptase inhibitors and randomized them 1:1 to continue lopinavir (+) ritonavir 2 tablets twice daily (n=174 and</p><p style="margin-left:8.9pt; margin-right:.8in">n=178, respectively) or replace lopinavir (+) ritonavir with raltegravir 400 mg twice daily (n=174 and n=176, respectively). Patients with a prior history of virological failure were not excluded and the number of previous antiretroviral therapies was not limited.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:59.85pt">These studies were terminated after the primary efficacy analysis at Week 24 because they failed to demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir. In both studies at Week 24, suppression of HIV RNA to less than 50 copies/ml was maintained in 84.4 % of the raltegravir group versus 90.6 % of the lopinavir (+) ritonavir group, (Non-completers = Failure). See section 4.4 regarding the need to administer raltegravir with two other active agents.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:-1.0pt"><em>Treatment-na&iuml;ve adult patients (400 mg twice daily)</em></p><p style="margin-left:8.9pt; margin-right:67.2pt">STARTMRK (multi-centre, randomised, double-blind, active-control trial) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a</p><p style="margin-left:8.9pt; margin-right:53.0pt">combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-na&iuml;ve HIV-infected patients with HIV RNA &gt; 5,000 copies/ml. Randomization was stratified by screening HIV RNA level</p><p style="margin-left:8.9pt; margin-right:-1.0pt">(&le; 50,000 copies/ml; and &gt; 50,000 copies/ml) and by hepatitis B or C status (positive or negative).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:53.05pt">Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:-1.0pt"><em>Results 48-week and 240-week analyses</em></p><p style="margin-left:8.9pt; margin-right:-1.0pt">With respect to the primary efficacy endpoint, the proportion (%) of patients achieving HIV RNA</p><p style="margin-left:8.9pt; margin-right:-1.0pt">&lt; 50 copies/ml at Week 48 was 241/280 (86.1 %) in the group receiving raltegravir and 230/281</p><p style="margin-left:8.9pt; margin-right:-1.0pt">(81.9 %) in the group receiving efavirenz. The treatment difference (raltegravir &ndash; efavirenz) was 4.2 %</p><p style="margin-left:8.9pt; margin-right:56.05pt">with an associated 95 % CI of (-1.9, 10.3) establishing that raltegravir is non-inferior to efavirenz (p- value for non-inferiority &lt; 0.001). At Week 240, the treatment difference (raltegravir &ndash; efavirenz) was</p><p style="margin-left:8.9pt; margin-right:-1.0pt">9.5 % with an associated 95 % CI of (1.7, 17.3). Week 48 and Week 240 outcomes for patients on the</p><p style="margin-left:8.9pt; margin-right:-1.0pt">recommended dose of raltegravir 400 mg twice daily from STARTMRK are shown in Table 3.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:-1.0pt"><strong>Table 3</strong></p><p style="margin-left:8.9pt; margin-right:-1.0pt"><strong>Efficacy Outcome at Weeks 48 and 240</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:8.9pt; margin-right:-3.5pt"><!--[if gte vml 1]><v:group id="_x0000_s1038" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:1.05pt;width:506.65pt;
 height:.1pt;z-index:-2143;mso-position-horizontal-relative:page'
 coordorigin="1349,21" coordsize="10133,2">
 <v:shape id="_x0000_s1039" style='position:absolute;left:1349;top:21;width:10133;
  height:2' coordorigin="1349,21" coordsize="10133,0" path="m1349,21r10133,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="678" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[endif]--><strong>STARTMRK Study</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><strong>48 Weeks&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240 Weeks</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt; text-align:right"><!--[if gte vml 1]><v:group
 id="_x0000_s1040" style='position:absolute;left:0;text-align:left;
 margin-left:268.9pt;margin-top:2.1pt;width:305.15pt;height:.1pt;z-index:-2142;
 mso-position-horizontal-relative:page' coordorigin="5378,42" coordsize="6103,2">
 <v:shape id="_x0000_s1041" style='position:absolute;left:5378;top:42;width:6103;
  height:2' coordorigin="5378,42" coordsize="6103,0" path="m5378,42r6104,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="409" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1042" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:13.05pt;width:506.65pt;
 height:63.8pt;z-index:-2141;mso-position-horizontal-relative:page' filled="f"
 stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><!--[endif]--><!--[if !mso]--><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><!--[endif]--><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:36.4pt; vertical-align:top; width:200.35pt"><p style="margin-left:3.5pt; margin-right:-1.0pt"><strong>Para</strong><strong>m</strong><strong>eter</strong></p></td><td style="height:36.4pt; vertical-align:top; width:76.75pt"><p style="margin-left:8.45pt; margin-right:10.0pt; text-align:center"><strong>40</strong><strong>0 mg twice daily</strong></p><p style="margin-left:15.5pt; margin-right:17.05pt; text-align:center"><strong>(</strong><strong>N = 281)</strong></p></td><td style="height:36.4pt; vertical-align:top; width:72.4pt"><p style="margin-left:17.35pt; margin-right:20.2pt; text-align:center"><strong>60</strong><strong>0 mg</strong></p><p style="margin-left:10.0pt; margin-right:12.55pt; text-align:center"><strong>a</strong><strong>t bedtime</strong></p><p style="margin-left:14.65pt; margin-right:-1.0pt"><strong>(</strong><strong>N = 282)</strong></p></td><td style="height:36.4pt; vertical-align:top; width:84.95pt"><p style="margin-left:14.55pt; margin-right:12.1pt; text-align:center"><strong>40</strong><strong>0 mg twice daily</strong></p><p style="margin-left:.3in; margin-right:19.15pt; text-align:center"><strong>(</strong><strong>N = 281)</strong></p></td><td style="height:36.4pt; vertical-align:top; width:72.2pt"><p style="margin-left:19.25pt; margin-right:17.65pt; text-align:center"><strong>60</strong><strong>0 mg</strong></p><p style="margin-left:12.1pt; margin-right:10.25pt; text-align:center"><strong>a</strong><strong>t bedtime</strong></p><p style="margin-left:16.75pt; margin-right:-1.0pt"><strong>(</strong><strong>N = 282)</strong></p></td></tr><tr><td style="height:27.4pt; vertical-align:top; width:200.35pt"><p style="margin-left:3.5pt; margin-right:-1.0pt"><strong>Percent HIV-RNA &lt; 50 copies/ml (95 % CI)</strong></p><p style="margin-left:21.1pt; margin-right:-1.0pt">All patients&dagger;</p></td><td style="height:27.4pt; vertical-align:top; width:76.75pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:14.95pt; margin-right:-1.0pt">86 (81, 90)</p></td><td style="height:27.4pt; vertical-align:top; width:72.4pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:12.35pt; margin-right:-1.0pt">82 (77, 86)</p></td><td style="height:27.4pt; vertical-align:top; width:84.95pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:21.05pt; margin-right:-1.0pt">71 (65, 76)</p></td><td style="height:27.4pt; vertical-align:top; width:72.2pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:14.45pt; margin-right:-1.0pt">61 (55, 67)</p></td></tr></tbody></table><p>&nbsp;</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--></p><p><strong>Raltegravir</strong></p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.5pt"><strong>Efavirenz</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.5pt"><strong>Raltegravir</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><strong>Efavirenz</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:36.5pt; margin-right:-1.0pt">Baseline Characteristic&Dagger;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:12.2pt; vertical-align:top; width:165.45pt"><p style="margin-left:4.5pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml</p></td><td style="height:12.2pt; vertical-align:top; width:73.7pt"><p style="margin-left:13.2pt; margin-right:-1.0pt">91 (85, 95)</p></td><td style="height:12.2pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">89 (83, 94)</p></td><td style="height:12.2pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">70 (62, 77)</p></td><td style="height:12.2pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">65 (56, 72)</p></td></tr><tr><td style="height:10.65pt; vertical-align:top; width:165.45pt"><p style="margin-left:51.9pt; margin-right:-1.0pt">&le; 100,000 copies/ml</p></td><td style="height:10.65pt; vertical-align:top; width:73.7pt"><p style="margin-left:13.2pt; margin-right:-1.0pt">93 (86, 97)</p></td><td style="height:10.65pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">89 (82, 94)</p></td><td style="height:10.65pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">72 (64, 80)</p></td><td style="height:10.65pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">58 (49, 66)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:165.45pt"><p style="margin-left:4.5pt; margin-right:-1.0pt">CD4-count &le; 50 cells/mm3</p></td><td style="height:11.5pt; vertical-align:top; width:73.7pt"><p style="margin-left:13.2pt; margin-right:-1.0pt">84 (64, 95)</p></td><td style="height:11.5pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">86 (67, 96)</p></td><td style="height:11.5pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">58 (37, 77)</p></td><td style="height:11.5pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">77 (58, 90)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:165.45pt"><p style="margin-left:51.9pt; margin-right:-1.0pt">&gt; 50 and &le; 200 cells/mm3</p></td><td style="height:11.5pt; vertical-align:top; width:73.7pt"><p style="margin-left:13.2pt; margin-right:-1.0pt">89 (81, 95)</p></td><td style="height:11.5pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">86 (77, 92)</p></td><td style="height:11.5pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">67 (57, 76)</p></td><td style="height:11.5pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">60 (50, 69)</p></td></tr><tr><td style="height:12.35pt; vertical-align:top; width:165.45pt"><p style="margin-left:51.9pt; margin-right:-1.0pt">&gt; 200 cells/mm3</p></td><td style="height:12.35pt; vertical-align:top; width:73.7pt"><p style="margin-left:13.2pt; margin-right:-1.0pt">94 (89, 98)</p></td><td style="height:12.35pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">92 (87, 96)</p></td><td style="height:12.35pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">76 (68, 82)</p></td><td style="height:12.35pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">60 (51, 68)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:165.45pt"><p style="margin-left:2.0pt; margin-right:-1.0pt">Viral Subtype Clade B</p></td><td style="height:11.45pt; vertical-align:top; width:73.7pt"><p style="margin-left:13.2pt; margin-right:-1.0pt">90 (85, 94)</p></td><td style="height:11.45pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">89 (83, 93)</p></td><td style="height:11.45pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">71 (65, 77)</p></td><td style="height:11.45pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">59 (52, 65)</p></td></tr><tr><td style="height:15.75pt; vertical-align:top; width:165.45pt"><p style="margin-left:59.5pt; margin-right:-1.0pt">Non-Clade B</p></td><td style="height:15.75pt; vertical-align:top; width:73.7pt"><p style="margin-left:10.7pt; margin-right:-1.0pt">96 (87, 100)</p></td><td style="height:15.75pt; vertical-align:top; width:76.35pt"><p style="margin-left:13.65pt; margin-right:-1.0pt">91 (78, 97)</p></td><td style="height:15.75pt; vertical-align:top; width:79.75pt"><p style="margin-left:18.45pt; margin-right:-1.0pt">68 (54, 79)</p></td><td style="height:15.75pt; vertical-align:top; width:63.3pt"><p style="margin-left:17.05pt; margin-right:-1.0pt">70 (54, 82)</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:9.9pt; margin-right:-3.5pt"><!--[if gte vml 1]><v:group id="_x0000_s1043" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:2.55pt;width:506.65pt;
 height:.1pt;z-index:-2140;mso-position-horizontal-relative:page'
 coordorigin="1349,51" coordsize="10133,2">
 <v:shape id="_x0000_s1044" style='position:absolute;left:1349;top:51;width:10133;
  height:2' coordorigin="1349,51" coordsize="10133,0" path="m1349,51r10133,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="678" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1045" style='position:absolute;left:0;text-align:left;
 margin-left:268.9pt;margin-top:16.7pt;width:305.15pt;height:.1pt;z-index:-2139;
 mso-position-horizontal-relative:page' coordorigin="5378,334" coordsize="6103,2">
 <v:shape id="_x0000_s1046" style='position:absolute;left:5378;top:334;width:6103;
  height:2' coordorigin="5378,334" coordsize="6103,0" path="m5378,334r6104,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="409" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><!--[endif]--><strong>STARTMRK Study</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><strong>48 Weeks&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240 Weeks</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:9.9pt; margin-right:-1.0pt"><strong>Para</strong><strong>m</strong><strong>eter</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:9.9pt; margin-right:-3.75pt"><!--[if gte vml 1]><v:group id="_x0000_s1047" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:1.1pt;width:506.65pt;
 height:.1pt;z-index:-2138;mso-position-horizontal-relative:page'
 coordorigin="1349,22" coordsize="10133,2">
 <v:shape id="_x0000_s1048" style='position:absolute;left:1349;top:22;width:10133;
  height:2' coordorigin="1349,22" coordsize="10133,0" path="m1349,22r10133,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="677" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[endif]--><strong>M</strong><strong>e</strong><strong>an CD4 Cell Change (95 % CI), cells/mm</strong><strong>3</strong></p><p>&nbsp;</p><p style="margin-left:1.25pt; margin-right:.25pt; text-align:center"><strong>Raltegravir</strong></p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>40</strong><strong>0 mg twice daily</strong></p><p style="margin-left:6.15pt; margin-right:5.15pt; text-align:center"><strong>(</strong><strong>N = 281)</strong></p><p>&nbsp;</p><p style="margin-left:.05pt; margin-right:-1.1pt; text-align:center"><strong>Efavirenz</strong></p><p style="margin-left:5.45pt; margin-right:4.75pt; text-align:center"><strong>60</strong><strong>0 mg</strong></p><p style="margin-left:-1.85pt; margin-right:-2.85pt; text-align:center"><strong>a</strong><strong>t bedtime</strong></p><p style="margin-left:2.75pt; margin-right:-1.0pt"><strong>(</strong><strong>N = 282)</strong></p><p>&nbsp;</p><p style="margin-left:1.25pt; margin-right:.25pt; text-align:center"><strong>Raltegravir</strong></p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>40</strong><strong>0 mg twice daily</strong></p><p style="margin-left:6.15pt; margin-right:5.15pt; text-align:center"><strong>(</strong><strong>N = 281)</strong></p><p>&nbsp;</p><p style="margin-left:.05pt; margin-right:17.2pt; text-align:center"><strong>Efavirenz</strong></p><p style="margin-left:5.45pt; margin-right:23.05pt; text-align:center"><strong>60</strong><strong>0 mg</strong></p><p style="margin-left:-1.85pt; margin-right:15.45pt; text-align:center"><strong>a</strong><strong>t bedtime</strong></p><p style="margin-left:2.75pt; margin-right:-1.0pt"><strong>(</strong><strong>N = 282)</strong></p><p>&nbsp;</p><p style="margin-left:27.55pt; margin-right:-1.0pt">All patients&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 189 (174, 204)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 163 (148, 178)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 374 (345, 403)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 312 (284, 339)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:37.5pt; margin-right:-1.0pt">Baseline Characteristic&Dagger;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:12.3pt; vertical-align:top; width:160.45pt"><p style="margin-left:2.0pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml</p></td><td style="height:12.3pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">196 (174, 219)</p></td><td style="height:12.3pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">192 (169, 214)</p></td><td style="height:12.3pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">392 (350, 435)</p></td><td style="height:12.3pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.6pt; margin-right:-1.0pt">329 (293, 364)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:160.45pt"><p style="margin-left:49.4pt; margin-right:-1.0pt">&le; 100,000 copies/ml</p></td><td style="height:11.5pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">180 (160, 200)</p></td><td style="height:11.5pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">134 (115, 153)</p></td><td style="height:11.5pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">350 (312, 388)</p></td><td style="height:11.5pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.6pt; margin-right:-1.0pt">294 (251, 337)</p></td></tr><tr><td style="height:10.65pt; vertical-align:top; width:160.45pt"><p style="margin-left:2.0pt; margin-right:-1.0pt">CD4-count &le; 50 cells/mm3</p></td><td style="height:10.65pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">170 (122, 218)</p></td><td style="height:10.65pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">152 (123, 180)</p></td><td style="height:10.65pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">304 (209, 399)</p></td><td style="height:10.65pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.6pt; margin-right:-1.0pt">314 (242, 386)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:160.45pt"><p style="margin-left:49.4pt; margin-right:-1.0pt">&gt; 50 and &le; 200 cells/mm3</p></td><td style="height:11.5pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">193 (169, 217)</p></td><td style="height:11.5pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">175 (151, 198)</p></td><td style="height:11.5pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">413 (360, 465)</p></td><td style="height:11.5pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.6pt; margin-right:-1.0pt">306 (264, 348)</p></td></tr><tr><td style="height:12.35pt; vertical-align:top; width:160.45pt"><p style="margin-left:49.4pt; margin-right:-1.0pt">&gt; 200 cells/mm3</p></td><td style="height:12.35pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">190 (168, 212)</p></td><td style="height:12.35pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">157 (134, 181)</p></td><td style="height:12.35pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">358 (321, 395)</p></td><td style="height:12.35pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.6pt; margin-right:-1.0pt">316 (272, 359)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:160.45pt"><p style="margin-left:-.5pt; margin-right:-1.0pt">Viral Subtype Clade B</p></td><td style="height:11.45pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">187 (170, 204)</p></td><td style="height:11.45pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">164 (147, 181)</p></td><td style="height:11.45pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">380 (346, 414)</p></td><td style="height:11.45pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.6pt; margin-right:-1.0pt">303 (272, 333)</p></td></tr><tr><td style="height:15.75pt; vertical-align:top; width:160.45pt"><p style="margin-left:56.95pt; margin-right:-1.0pt">Non-Clade B</p></td><td style="height:15.75pt; vertical-align:top; width:74.95pt"><p style="margin-left:8.2pt; margin-right:-1.0pt">189 (153, 225)</p></td><td style="height:15.75pt; vertical-align:top; width:77.65pt"><p style="margin-left:7.45pt; margin-right:-1.0pt">156 (121, 190)</p></td><td style="height:15.75pt; vertical-align:top; width:79.7pt"><p style="margin-left:10.95pt; margin-right:-1.0pt">332 (275, 388)</p></td><td style="height:15.75pt; vertical-align:top; width:70.85pt"><p style="margin-left:9.5pt; margin-right:-1.0pt">329 (260, 398)</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:17.95pt; margin-right:30.25pt; text-indent:-8.05pt"><!--[if gte vml 1]><v:group id="_x0000_s1049" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:.75pt;width:506.65pt;
 height:.1pt;z-index:-2137;mso-position-horizontal-relative:page'
 coordorigin="1349,15" coordsize="10133,2">
 <v:shape id="_x0000_s1050" style='position:absolute;left:1349;top:15;width:10133;
  height:2' coordorigin="1349,15" coordsize="10133,0" path="m1349,15r10133,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="677" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[endif]-->&dagger; Non-completer is failure imputation: patients who discontinued prematurely are imputed as failure thereafter. Percent of patients with response and associated 95 % confidence interval (CI) are reported.</p><p style="margin-left:9.9pt; margin-right:-1.0pt">&Dagger; For analysis by prognostic factors, virologic failures were carried forward for percent &lt; 50 and 400 copies/ml. For mean CD4 changes, baseline-carry-</p><p style="margin-left:17.95pt; margin-right:-1.0pt">forward was used for virologic failures.</p><p style="margin-left:9.9pt; margin-right:-1.0pt">Notes: The analysis is based on all available data.</p><p style="margin-left:5.7pt; margin-right:-1.0pt"><u>&nbsp;</u><u>Raltegravir and efavirenz were administered with emtricitabine (+) tenofovir disoproxil fumarate. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:9.9pt; margin-right:-1.0pt"><em>Treatment-na&iuml;ve adult patients (1,200 mg [2 x 600 mg] once daily)</em></p><p style="margin-left:9.9pt; margin-right:72.1pt">ONCEMRK (multi-centre, randomised, double-blind, active-control trial) evaluated the safety and anti-retroviral activity of raltegravir 1,200 mg once daily + emtricitabine (+) tenofovir disoproxil</p><p style="margin-left:9.9pt; margin-right:53.55pt">fumarate vs. raltegravir 400 mg twice daily, in combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-na&iuml;ve HIV-infected patients with HIV RNA &gt; 1,000 copies/ml. Randomization</p><p style="margin-left:9.9pt; margin-right:68.3pt">was stratified by screening HIV RNA level (&le; 100,000 copies/ml; and &gt; 100,000 copies/ml) and by hepatitis B or C status (positive or negative).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:9.9pt; margin-right:52.95pt">Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 1,200 mg once daily and the group receiving raltegravir 400 mg twice</p><p style="margin-left:9.9pt; margin-right:-1.0pt">daily.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:9.9pt; margin-right:-1.0pt"><em>Results 48-week analyses</em></p><p style="margin-left:9.9pt; margin-right:-1.0pt">With respect to the primary efficacy endpoint, the proportion (%) of patients achieving HIV RNA</p><p style="margin-left:9.9pt; margin-right:51.95pt">&lt; 40 copies/ml at Week 48 was 472/531(88.9%) in the group receiving raltegravir 1,200 mg once daily and 235/266 (88.3%) in the group receiving raltegravir 400 mg twice daily. The treatment difference</p><p style="margin-left:9.9pt; margin-right:-1.0pt">(raltegravir 1,200 mg once daily-raltegravir 400 mg twice daily) was 0.5% with an associated 95% CI</p><p style="margin-left:9.9pt; margin-right:1.0in">of (-4.2, 5.2) establishing that raltegravir 1,200 mg once daily is non-inferior to raltegravir 400 mg twice daily. Week 48 outcomes from ONCEMRK are shown in Table 4.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.9pt; margin-right:-1.0pt"><strong>Table 4</strong></p><p style="margin-left:9.9pt; margin-right:-3.65pt"><!--[if gte vml 1]><v:group
 id="_x0000_s1051" style='position:absolute;left:0;text-align:left;
 margin-left:67.45pt;margin-top:13.7pt;width:476.05pt;height:.1pt;z-index:-2136;
 mso-position-horizontal-relative:page' coordorigin="1349,274" coordsize="9521,2">
 <v:shape id="_x0000_s1052" style='position:absolute;left:1349;top:274;width:9521;
  height:2' coordorigin="1349,274" coordsize="9521,0" path="m1349,274r9521,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="637" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /><!--[endif]--><strong>Efficacy Outcome at Weeks 48</strong></p><p style="margin-left:9.9pt; margin-right:-1.0pt"><strong>ONCEMRK Study</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-3.5pt"><strong>Raltegravir</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.5pt"><!--[if gte vml 1]><v:group
 id="_x0000_s1053" style='position:absolute;margin-left:313.8pt;margin-top:13.2pt;
 width:229.7pt;height:.1pt;z-index:-2135;mso-position-horizontal-relative:page'
 coordorigin="6276,264" coordsize="4594,2">
 <v:shape id="_x0000_s1054" style='position:absolute;left:6276;top:264;width:4594;
  height:2' coordorigin="6276,264" coordsize="4594,0" path="m6276,264r4594,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="309" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" /><!--[endif]--><strong>48 Weeks</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><strong>Raltegravir</strong></p><p>&nbsp;</p><p style="margin-left:9.9pt; margin-right:-1.0pt"><strong>Para</strong><strong>m</strong><strong>eter</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:9.9pt; margin-right:-3.5pt"><!--[if gte vml 1]><v:group id="_x0000_s1055" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:-.4pt;width:476.05pt;
 height:.1pt;z-index:-2134;mso-position-horizontal-relative:page'
 coordorigin="1349,-8" coordsize="9521,2">
 <v:shape id="_x0000_s1056" style='position:absolute;left:1349;top:-8;width:9521;
  height:2' coordorigin="1349,-8" coordsize="9521,0" path="m1349,-8r9521,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="637" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /><!--[endif]--><strong>Percent HIV-RNA &lt; 40 copies/ml (95 % CI)</strong></p><p>&nbsp;</p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>60</strong><strong>0 mg (1,200 mg once daily)</strong></p><p style="margin-left:15.9pt; margin-right:14.45pt; text-align:center"><strong>(</strong><strong>N = 531)</strong></p><p>&nbsp;</p><p style="margin-left:-.85pt; margin-right:58.55pt; text-align:center; text-indent:-.65pt"><strong>40</strong><strong>0 mg twice daily (N = 266)</strong></p><p>&nbsp;</p><p style="margin-left:27.55pt; margin-right:-1.0pt">All patients&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 88.9 (85.9, 91.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 88.3 (83.9, 91.9)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:37.5pt; margin-right:-1.0pt">Baseline Characteristic&Dagger;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.0pt; vertical-align:top; width:186.05pt"><p style="margin-left:2.0pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml</p></td><td style="height:13.0pt; vertical-align:top; width:145.7pt"><p style="margin-left:54.9pt; margin-right:-1.0pt">86.7 (80.0, 91.8)</p></td><td style="height:13.0pt; vertical-align:top; width:92.95pt"><p style="margin-left:24.15pt; margin-right:-1.0pt">83.8 (73.4, 91.3)</p></td></tr><tr><td style="height:10.65pt; vertical-align:top; width:186.05pt"><p style="margin-left:49.4pt; margin-right:-1.0pt">&le; 100,000 copies/ml</p></td><td style="height:10.65pt; vertical-align:top; width:145.7pt"><p style="margin-left:54.9pt; margin-right:-1.0pt">97.2 (94.9, 98.7)</p></td><td style="height:10.65pt; vertical-align:top; width:92.95pt"><p style="margin-left:24.15pt; margin-right:-1.0pt">97.7 (94.3, 99.4)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:186.05pt"><p style="margin-left:2.0pt; margin-right:-1.0pt">CD4-count &le; 200 cells/mm3</p></td><td style="height:11.5pt; vertical-align:top; width:145.7pt"><p style="margin-left:54.9pt; margin-right:-1.0pt">85.1 (74.3, 92.6)</p></td><td style="height:11.5pt; vertical-align:top; width:92.95pt"><p style="margin-left:24.0pt; margin-right:-1.0pt">87.9 (71.8, 96.6)</p></td></tr><tr><td style="height:12.35pt; vertical-align:top; width:186.05pt"><p style="margin-left:49.4pt; margin-right:-1.0pt">&gt; 200 cells/mm3</p></td><td style="height:12.35pt; vertical-align:top; width:145.7pt"><p style="margin-left:54.9pt; margin-right:-1.0pt">95.6 (93.2, 97.3)</p></td><td style="height:12.35pt; vertical-align:top; width:92.95pt"><p style="margin-left:24.0pt; margin-right:-1.0pt">94.5 (90.6, 97.1)</p></td></tr><tr><td style="height:15.7pt; vertical-align:top; width:186.05pt"><p style="margin-left:-.5pt; margin-right:-1.0pt">Viral Subtype Clade B</p></td><td style="height:15.7pt; vertical-align:top; width:145.7pt"><p style="margin-left:54.9pt; margin-right:-1.0pt">94.6 (91.4, 96.8)</p></td><td style="height:15.7pt; vertical-align:top; width:92.95pt"><p style="margin-left:24.0pt; margin-right:-1.0pt">93.7 (89.0, 96.8)</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:8.9pt; margin-right:-3.5pt"><!--[if gte vml 1]><v:group
 id="_x0000_s1057" style='position:absolute;left:0;text-align:left;
 margin-left:67.45pt;margin-top:2.55pt;width:476.05pt;height:.1pt;z-index:-2133;
 mso-position-horizontal-relative:page' coordorigin="1349,51" coordsize="9521,2">
 <v:shape id="_x0000_s1058" style='position:absolute;left:1349;top:51;width:9521;
  height:2' coordorigin="1349,51" coordsize="9521,0" path="m1349,51r9521,e"
  filled="f" strokeweight="1.54pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="637" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image013.gif" /><!--[endif]--><strong>ONCEMRK Study</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.5pt"><!--[if gte vml 1]><v:group id="_x0000_s1059" style='position:absolute;
 margin-left:313.8pt;margin-top:-1pt;width:229.7pt;height:.1pt;z-index:-2132;
 mso-position-horizontal-relative:page' coordorigin="6276,-20" coordsize="4594,2">
 <v:shape id="_x0000_s1060" style='position:absolute;left:6276;top:-20;width:4594;
  height:2' coordorigin="6276,-20" coordsize="4594,0" path="m6276,-20r4594,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="309" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" /><!--[endif]--><strong>Raltegravir</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.5pt"><strong>48 Weeks</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><strong>Raltegravir</strong></p><p>&nbsp;</p><p style="margin-left:8.9pt; margin-right:-3.5pt"><strong>Para</strong><strong>m</strong><strong>eter</strong></p><p>&nbsp;</p><p style="margin-left:-.85pt; margin-right:-1.85pt; text-align:center"><strong>60</strong><strong>0 mg (1,200 mg once daily)</strong></p><p style="margin-left:15.9pt; margin-right:14.45pt; text-align:center"><!--[if gte vml 1]><v:group
 id="_x0000_s1061" style='position:absolute;left:0;text-align:left;
 margin-left:67.45pt;margin-top:12.1pt;width:476.05pt;height:.1pt;z-index:-2131;
 mso-position-horizontal-relative:page' coordorigin="1349,242" coordsize="9521,2">
 <v:shape id="_x0000_s1062" style='position:absolute;left:1349;top:242;width:9521;
  height:2' coordorigin="1349,242" coordsize="9521,0" path="m1349,242r9521,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="637" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /><!--[endif]--><strong>(</strong><strong>N = 531)</strong></p><p>&nbsp;</p><p style="margin-left:-.85pt; margin-right:28.55pt; text-align:center; text-indent:-.65pt"><strong>40</strong><strong>0 mg twice daily (N = 266)</strong></p><p>&nbsp;</p><p style="margin-left:101.55pt; margin-right:-1.0pt">Non-Clade B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 93.6 (89.1, 96.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 93.2 (84.9, 97.8)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:-1.0pt"><!--[if gte vml 1]><v:group
 id="_x0000_s1063" style='position:absolute;left:0;text-align:left;
 margin-left:67.45pt;margin-top:3.05pt;width:476.05pt;height:.1pt;z-index:-2130;
 mso-position-horizontal-relative:page' coordorigin="1349,61" coordsize="9521,2">
 <v:shape id="_x0000_s1064" style='position:absolute;left:1349;top:61;width:9521;
  height:2' coordorigin="1349,61" coordsize="9521,0" path="m1349,61r9521,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="637" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image014.gif" /><!--[endif]--><strong>M</strong><strong>e</strong><strong>an CD4 Cell Change (95 % CI), cells/mm</strong><strong>3</strong></p><p style="margin-left:26.55pt; margin-right:-1.0pt">All patients&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 232 (215, 249)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 234 (213, 255)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:36.5pt; margin-right:-1.0pt">Baseline Characteristic&Dagger;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.0pt; vertical-align:top; width:227.1pt"><p style="margin-left:41.15pt; margin-right:-1.0pt">HIV-RNA &gt; 100,000 copies/ml</p></td><td style="height:13.0pt; vertical-align:top; width:143.85pt"><p style="margin-left:56.8pt; margin-right:-1.0pt">276 (245, 308)</p></td><td style="height:13.0pt; vertical-align:top; width:105.05pt"><p style="margin-left:27.8pt; margin-right:-1.0pt">256 (218, 294)</p></td></tr><tr><td style="height:10.65pt; vertical-align:top; width:227.1pt"><p style="margin-left:88.55pt; margin-right:-1.0pt">&le; 100,000 copies/ml</p></td><td style="height:10.65pt; vertical-align:top; width:143.85pt"><p style="margin-left:56.8pt; margin-right:-1.0pt">214 (194, 235)</p></td><td style="height:10.65pt; vertical-align:top; width:105.05pt"><p style="margin-left:27.8pt; margin-right:-1.0pt">225 (199, 251)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:227.1pt"><p style="margin-left:41.15pt; margin-right:-1.0pt">CD4 count &le; 200 cells/mm3</p></td><td style="height:11.45pt; vertical-align:top; width:143.85pt"><p style="margin-left:56.8pt; margin-right:-1.0pt">209 (176, 243)</p></td><td style="height:11.45pt; vertical-align:top; width:105.05pt"><p style="margin-left:27.8pt; margin-right:-1.0pt">209 (172, 245)</p></td></tr><tr><td style="height:12.35pt; vertical-align:top; width:227.1pt"><p style="margin-left:88.55pt; margin-right:-1.0pt">&gt; 200 cells/mm3</p></td><td style="height:12.35pt; vertical-align:top; width:143.85pt"><p style="margin-left:56.8pt; margin-right:-1.0pt">235 (216, 255)</p></td><td style="height:12.35pt; vertical-align:top; width:105.05pt"><p style="margin-left:27.8pt; margin-right:-1.0pt">238 (214, 262)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:227.1pt"><p style="margin-left:38.65pt; margin-right:-1.0pt">Viral Subtype Clade B</p></td><td style="height:11.5pt; vertical-align:top; width:143.85pt"><p style="margin-left:56.8pt; margin-right:-1.0pt">232 (209, 254)</p></td><td style="height:11.5pt; vertical-align:top; width:105.05pt"><p style="margin-left:27.8pt; margin-right:-1.0pt">240 (213, 266)</p></td></tr><tr><td style="height:15.75pt; vertical-align:top; width:227.1pt"><p style="margin-left:94.35pt; margin-right:75.25pt; text-align:center">Non-Clade B</p></td><td style="height:15.75pt; vertical-align:top; width:143.85pt"><p style="margin-left:56.8pt; margin-right:-1.0pt">233 (205, 261)</p></td><td style="height:15.75pt; vertical-align:top; width:105.05pt"><p style="margin-left:27.8pt; margin-right:-1.0pt">226 (191, 261)</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:16.95pt; margin-right:13.85pt; text-indent:-8.05pt"><!--[if gte vml 1]><v:group id="_x0000_s1065" style='position:absolute;
 left:0;text-align:left;margin-left:67.45pt;margin-top:2.85pt;width:476.05pt;
 height:.1pt;z-index:-2129;mso-position-horizontal-relative:page'
 coordorigin="1349,57" coordsize="9521,2">
 <v:shape id="_x0000_s1066" style='position:absolute;left:1349;top:57;width:9521;
  height:2' coordorigin="1349,57" coordsize="9521,0" path="m1349,57r9521,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="637" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image014.gif" /><!--[endif]-->&dagger; Non-completer is failure imputation: patients who discontinued prematurely are imputed as failure thereafter. Percent of patients with response and associated 95 % confidence interval (CI) are reported.</p><p style="margin-left:8.9pt; margin-right:-1.0pt">&Dagger; For analysis by prognostic factors, virologic failures were carried forward for percent &lt; 40 copies/ml. For mean CD4 changes, baseline-carry-</p><p style="margin-left:16.95pt; margin-right:-1.0pt">forward was used for virologic failures.</p><p style="margin-left:8.9pt; margin-right:-1.0pt"><!--[if gte vml 1]><v:group id="_x0000_s1067" style='position:absolute;
 left:0;text-align:left;margin-left:66.7pt;margin-top:10.05pt;width:476.75pt;
 height:.1pt;z-index:-2128;mso-position-horizontal-relative:page'
 coordorigin="1334,201" coordsize="9535,2">
 <v:shape id="_x0000_s1068" style='position:absolute;left:1334;top:201;width:9535;
  height:2' coordorigin="1334,201" coordsize="9535,0" path="m1334,201r9536,e"
  filled="f" strokeweight="1.06pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="638" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image015.gif" /><!--[endif]-->Raltegravir 1,200 mg QD and raltegravir 400 mg BID were administered with emtricitabine (+) tenofovir disoproxil fumarate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:8.9pt; margin-right:-1.0pt"><u>Absorption</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:25.6pt">As demonstrated in healthy volunteers administered single oral doses of raltegravir in the fasted state, raltegravir is rapidly absorbed with a tmax of approximately 3 hours postdose. Raltegravir AUC and Cmax increase dose proportionally over the dose range 100 mg to 1,600 mg. Raltegravir C12 hr increases dose proportionally over the dose range of 100 to 800 mg and increases slightly less than dose proportionally over the dose range 100 mg to 1,600 mg.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:34.25pt">With twice-daily dosing, pharmacokinetic steady state is achieved rapidly, within approximately the first 2 days of dosing. There is little to no accumulation in AUC and Cmax and evidence of slight accumulation in C12 hr. The absolute bioavailability of raltegravir has not been established.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:21.75pt">Raltegravir 1,200 mg once daily is also rapidly absorbed with median Tmax ~1.5 to 2 hours in the fasted state and generates a sharper absorption peak with a tendency to higher Cmax in comparison to raltegravir twice daily (1 x 400 mg tablet twice daily). In addition, relative to the raltegravir 400 mg formulation the raltegravir 600 mg formulation used in the 1,200 mg (2 x 600 mg) once daily dosing regimen has higher relative bioavailability (by 21 to 66%). Once absorbed, both formulations of raltegravir exhibit similar systemic pharmacokinetics. In patients, after 1,200 mg once daily raltegravir dosing, steady state AUC0-24 was 53.7 h&middot;&mu;M, C24 was 75.6 nM, and median Tmax was 1.50 h.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:23.4pt">Raltegravir 400 mg twice daily may be administered with or without food. Raltegravir was administered without regard to food in the pivotal safety and efficacy studies in HIV-infected patients. Administration of multiple doses of raltegravir following a moderate-fat meal did not affect raltegravir AUC to a clinically meaningful degree with an increase of 13 % relative to fasting. Raltegravir C12 hr was 66 % higher and Cmax was 5 % higher following a moderate-fat meal compared to fasting. Administration of raltegravir following a high-fat meal increased AUC and Cmax by approximately</p><p style="margin-left:8.9pt; margin-right:47.45pt">2-fold and increased C12 hr by 4.1-fold. Administration of raltegravir following a low-fat meal decreased AUC and Cmax by 46 % and 52 %, respectively; C12 hr was essentially unchanged. Food</p><p style="margin-left:8.9pt; margin-right:-1.0pt">appears to increase pharmacokinetic variability relative to fasting.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.9pt; margin-right:30.95pt">Raltegravir 600 mg tablets (2 x 600 mg once daily) may be administered with or without food. A single dose food effect study demonstrated that the 1,200 mg once daily had similar or smaller food effects when studied under high-fat and low-fat meal conditions when compared to the 400 mg twice</p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:18.35pt">daily. Administration of a low fat meal with raltegravir 1,200 mg once daily resulted in a 42% decrease in AUC0-last, 52% decrease in Cmax, and 16% decrease in C24hr. Administration of a high fat meal resulted in a 1.9% increase in AUC0-last, 28% decrease in Cmax, and 12% decrease in C24 hr.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:16.25pt">Overall, considerable variability was observed in the pharmacokinetics of raltegravir. For observed C12 hr in BENCHMRK 1 and 2 the coefficient of variation (CV) for inter-subject variability = 212 % and the CV for intra-subject variability = 122 %. Sources of variability may include differences in</p><p style="margin-left:5.9pt; margin-right:-1.0pt">co-administration with food and concomitant medicines.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Distribution</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">Raltegravir is approximately 83 % bound to human plasma protein over the concentration range of 2 to</p><p style="margin-left:5.9pt; margin-right:-1.0pt">10 &micro;M.</p><p style="margin-left:5.9pt; margin-right:31.0pt">Raltegravir readily crossed the placenta in rats, but did not penetrate the brain to any appreciable extent.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:5.85pt">In two studies of HIV-1 infected patients who received raltegravir 400 mg twice daily, raltegravir was readily detected in the cerebrospinal fluid. In the first study (n=18), the median cerebrospinal fluid concentration was 5.8 % (range 1 to 53.5 %) of the corresponding plasma concentration. In the second study (n=16), the median cerebrospinal fluid concentration was 3 % (range 1 to 61 %) of the corresponding plasma concentration. These median proportions are approximately 3- to 6-fold lower than the free fraction of raltegravir in plasma.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Biotransformation and excretion</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:7.4pt">The apparent terminal half-life of raltegravir is approximately 9 hours, with a shorter &alpha;-phase half-life (~1 hour) accounting for much of the AUC. Following administration of an oral dose of radiolabeled raltegravir, approximately 51 and 32 % of the dose was excreted in faeces and urine, respectively. In faeces, only raltegravir was present, most of which is likely to be derived from hydrolysis of raltegravir-glucuronide secreted in bile as observed in preclinical species. Two components, namely raltegravir and raltegravir-glucuronide, were detected in urine and accounted for approximately 9 and</p><p style="margin-left:5.9pt; margin-right:5.35pt">23 % of the dose, respectively. The major circulating entity was raltegravir and represented approximately 70 % of the total radioactivity; the remaining radioactivity in plasma was accounted for</p><p style="margin-left:5.9pt; margin-right:-1.0pt">by raltegravir-glucuronide. Studies using isoform-selective chemical inhibitors and cDNA-expressed</p><p style="margin-left:5.9pt; margin-right:9.2pt">UDP-glucuronosyltransferases (UGT) show that UGT1A1 is the main enzyme responsible for the formation of raltegravir-glucuronide. Thus the data indicate that the major mechanism of clearance of</p><p style="margin-left:5.9pt; margin-right:-1.0pt">raltegravir in humans is UGT1A1-mediated glucuronidation.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>UGT1A1 Polymorphism</em></p><p style="margin-left:5.9pt; margin-right:7.5pt">In a comparison of 30 subjects with *28/*28 genotype to 27 subjects with wild-type genotype, the geometric mean ratio (90 % CI) of AUC was 1.41 (0.96, 2.09) and the geometric mean ratio of C12 hr was 1.91 (1.43, 2.55). Dose adjustment is not considered necessary in subjects with reduced UGT1A1 activity due to genetic polymorphism.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Special populations</u></p><p style="margin-left:0in; margin-right:0in"><u>&nbsp;</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Elderly</em></p><p style="margin-left:5.9pt; margin-right:17.45pt">There was no clinically meaningful effect of age on raltegravir pharmacokinetics over the age range studied with raltegravir 400 mg twice daily. There was no clinically meaningful effect of age on</p><p style="margin-left:5.9pt; margin-right:-1.0pt">raltegravir pharmacokinetics over the age range studied in Protocol 292 with raltegravir 1,200 mg</p><p style="margin-left:5.9pt; margin-right:-1.0pt">(2 x 600 mg) once daily.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Gender, race, ethnicity and body weight</em></p><p style="margin-left:5.9pt; margin-right:9.8pt">There were no clinically important pharmacokinetic differences due to gender, race, ethnicity or body weight in adults for raltegravir 400 mg twice daily, and no clinically meaningful effect on raltegravir pharmacokinetics was concluded. For raltegravir 1,200 mg (2 x 600 mg) once daily, population</p><p style="margin-left:5.9pt; margin-right:28.65pt">PK analysis also demonstrated that the impacts of gender, race, ethnicity and body weight are not clinically meaningful.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Renal impairment</em></p><p style="margin-left:5.9pt; margin-right:15.6pt">Renal clearance of unchanged medicinal product is a minor pathway of elimination. In adults, there were no clinically important pharmacokinetic differences between patients with severe renal insufficiency and healthy subjects (see section 4.2 of the 400 mg twice daily SmPC). Because the extent to which raltegravir may be dialysable is unknown, dosing before a dialysis session should be avoided. No renal impairment study was conducted with raltegravir 1,200 mg once daily however, based on results with the 400 mg twice daily tablet, no clinically meaningful effect is anticipated.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><em>Hepatic impairment</em></p><p style="margin-left:5.9pt; margin-right:10.6pt">Raltegravir is eliminated primarily by glucuronidation in the liver. In adults, there were no clinically important pharmacokinetic differences between patients with moderate hepatic insufficiency and healthy subjects. The effect of severe hepatic insufficiency on the pharmacokinetics of raltegravir has not been studied (see sections 4.2 and 4.4 of the 400 mg twice daily SmPC). No hepatic impairment study has been conducted with raltegravir 1,200 mg once daily, however, based on results with the</p><p style="margin-left:5.9pt; margin-right:17.3pt">400 mg twice daily tablet, no clinically meaningful effect is expected for mild and moderate hepatic impairment.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:6.15pt">Non-clinical toxicology studies, including conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, developmental toxicity and juvenile toxicity, have been conducted with</p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:14.1pt">raltegravir in mice, rats, dogs and rabbits. Effects at exposure levels sufficiently in excess of clinical exposure levels indicate no special hazard for humans.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Mutagenicity</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.15pt">No evidence of mutagenicity or genotoxicity was observed in <em>in vitro </em>microbial mutagenesis (Ames) tests, <em>in vitro </em>alkaline elution assays for DNA breakage and <em>in vitro </em>and <em>in vivo </em>chromosomal aberration studies.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Carcinogenicity</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:8.3pt">A carcinogenicity study of raltegravir in mice did not show any carcinogenic potential. At the highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic exposure was similar to that at the clinical dose of 1,200 mg once daily. In rats, tumours (squamous cell carcinoma) of the nose/nasopharynx were identified at 300 and 600 mg/kg/day in females and at 300 mg/kg/day in</p><p style="margin-left:5.9pt; margin-right:2.75pt">males. This neoplasia could result from local deposition and/or aspiration of drug on the mucosa of the nose/nasopharynx during oral gavage dosing and subsequent chronic irritation and inflammation; it is likely that it is of limited relevance for the intended clinical use. At the NOAEL, systemic exposure was similar to that at the clinical dose of 1,200 mg once daily. Standard genotoxicity studies to</p><p style="margin-left:5.9pt; margin-right:-1.0pt">evaluate mutagenicity and clastogenicity were negative.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Developmental toxicity</u></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:8.2pt">Raltegravir was not teratogenic in developmental toxicity studies in rats and rabbits. A slight increase in incidence of supernumerary ribs was observed in rat pups of dams exposed to raltegravir at approximately 4.4-fold human exposure at 1,200 mg once daily based on AUC0-24 hr. No development effects were seen at 3.4-fold human exposure at 1,200 mg once daily based on AUC0-24 hr (see</p><p style="margin-left:5.9pt; margin-right:-1.0pt">section 4.6). Similar findings were not observed in rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt"><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Tablet core</u></p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Microcrystalline cellulose</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Hypromellose 2910</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Magnesium stearate</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Croscarmellose sodium</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt"><u>Fil</u><u>m</u><u>-</u><u>coating</u></p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Lactose monohydrate</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Hypromellose 2910</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Titanium dioxide</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Triacetin</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Iron oxide yellow</p><p style="margin-left:5.9pt; margin-right:-1.0pt">- Black iron oxide</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.9pt; margin-right:-1.0pt">The tablet may also contain trace amount of carnauba wax.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt">Keep the bottle tightly closed, with the desiccant in order to protect from moisture.</p><p style="margin-left:5.9pt; margin-right:-1.0pt">Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:2.25pt">High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure, induction seal and silica gel dessicant.</p><p style="margin-left:5.1pt; margin-right:-1.0pt">One pack size is available: 1 bottle with 60 tablets.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.9pt; margin-right:-1.0pt">No special requirements for disposal.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme Ltd, 120 Moorgate, London, EC2M 6UR, United Kingdom
Manufacturer:
MSD International GmbH (Singapore Branch), 70 Tuas West Drive, Singapore



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>